{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 452, 'offsetInEndSection': 569, 'text': 'CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35633976'}, {'offsetInBeginSection': 1208, 'offsetInEndSection': 1359, 'text': 'We will extract data based on the Checklist for\\xa0Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS), ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35321760'}, {'offsetInBeginSection': 688, 'offsetInEndSection': 807, 'text': 'Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS-PF).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35196337'}, {'offsetInBeginSection': 892, 'offsetInEndSection': 993, 'text': 'Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35493941'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 267, 'text': 'The CHARMS (critical appraisal and data extraction for systematic reviews of prediction modelling studies) checklist was created to provide methodological appraisals of predictive models, based on the best available scientific evidence and through systematic reviews.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32583899'}, {'offsetInBeginSection': 53, 'offsetInEndSection': 298, 'text': 'However, these models should be developed appropriately (CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modeling Studies [CHARMS] and Prediction model Risk Of Bias ASsessment Tool [PROBAST] statements).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31762119'}, {'offsetInBeginSection': 621, 'offsetInEndSection': 842, 'text': 'tudies with model updating. Data was extracted following the Checklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS) checklist.PRIMARY AND SECONDARY OUTCOME MEA', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31439598'}, {'offsetInBeginSection': 693, 'offsetInEndSection': 931, 'text': 'Data collection was guided by the checklist for critical appraisal and data extraction for systematic reviews (CHARMS) and applicability and methodological quality assessment by the prediction model risk of bias assessment tool (PROBAST).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32453803'}, {'offsetInBeginSection': 351, 'offsetInEndSection': 509, 'text': 'Studies were assessed using the checklist for critical appraisal and data extraction for systematic reviews of prediction modeling studies (CHARMS) checklist.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31090660'}, {'offsetInBeginSection': 321, 'offsetInEndSection': 688, 'text': 'methods in oncology. We used the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) statement, Prediction model Risk Of Bias ASsessment Tool (PROBAST) and CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS) to assess the methodological conduct of i', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35395724'}, {'offsetInBeginSection': 372, 'offsetInEndSection': 591, 'text': 'inclusion criteria). We followed the CHARMS recommendations (Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies), extracting the information from its 11 domains (Source of data', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33492724'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 116, 'text': 'Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25314315'}, {'offsetInBeginSection': 678, 'offsetInEndSection': 847, 'text': 'The CHARMS (Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies) checklist was used for data extraction and quality assessment.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28284255'}, {'offsetInBeginSection': 190, 'offsetInEndSection': 1256, 'text': 'ion making. Systematic reviews of prognostic model studies can help identify prognostic models that need to further be validated or are ready to be implemented in healthcare.OBJECTIVES: To provide a step-by-step guidance on how to conduct and read a systematic review of prognostic model studies and to provide an overview of methodology and guidance available for every step of the review progress.SOURCES: Published, peer-reviewed guidance articles.CONTENT: We describe the following steps for conducting a systematic review of prognosis studies: 1) Developing the review question using the Population, Index model, Comparator model, Outcome(s), Timing, Setting format, 2) Searching and selection of articles, 3) Data extraction using the Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies (CHARMS) checklist, 4) Quality and risk of bias assessment using the Prediction model Risk Of Bias ASsessment (PROBAST) tool, 5) Analysing data and undertaking quantitative meta-analysis, and 6) Presenting summary of findings, inte', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35934199'}, {'offsetInBeginSection': 1028, 'offsetInEndSection': 1211, 'text': 'te, or status of the publication. To carry out the systematic review, the CHARMS (Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies) guidel', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33407048'}, {'offsetInBeginSection': 1042, 'offsetInEndSection': 1457, 'text': 'The authors did not put any restrictions on the models included in their study regarding the model setting, prediction horizon or outcomes.Data extraction and synthesis Checklists of critical appraisal and data extraction for systematic reviews of prediction modelling studies (CHARMS) and prediction model risk of bias assessment tool (PROBAST) were used to guide developing of a standardised data extraction form.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32978532'}, {'offsetInBeginSection': 764, 'offsetInEndSection': 1015, 'text': 'We critically appraised these models by means of criteria derived from the CHARMS (CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modeling Studies) and PROBAST (Prediction model Risk Of Bias ASsessment Tool).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34413828'}, {'offsetInBeginSection': 116, 'offsetInEndSection': 266, 'text': 'ist for critical Appraisal and data extraction for systematic Reviews of prediction Modeling Studies [CHARMS] and Prediction model Risk Of Bias ASsess', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31762119'}, {'offsetInBeginSection': 690, 'offsetInEndSection': 840, 'text': 't for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS) checklist.PRIMARY AND SECONDARY OUTCOME M', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31439598'}, {'offsetInBeginSection': 405, 'offsetInEndSection': 555, 'text': 'the CHARMS recommendations (Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies), extracting the information', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33492724'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'The CHARMS (critical appraisal and data extraction for systematic reviews of prediction modelling studies) checklist was created to provide methodolog', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32583899'}, {'offsetInBeginSection': 389, 'offsetInEndSection': 539, 'text': 'ist for critical appraisal and data extraction for systematic reviews of prediction modeling studies (CHARMS) checklist. In total 89,959 citations wer', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31090660'}, {'offsetInBeginSection': 864, 'offsetInEndSection': 1014, 'text': 'acted the data. We used the Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS) checklist for the ri', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35493941'}, {'offsetInBeginSection': 517, 'offsetInEndSection': 667, 'text': 'ical appraisal and data extraction for systematic reviews of prediction modeling studies (CHARMS) and the prediction model risk of bias assessment too', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33364802'}, {'offsetInBeginSection': 461, 'offsetInEndSection': 611, 'text': 'nalysed (domains of CHARMS, Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies) the following: source of da', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31441567'}, {'offsetInBeginSection': 690, 'offsetInEndSection': 850, 'text': 't for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS) checklist.PRIMARY AND SECONDARY OUTCOME MEASURES: P', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31439598'}, {'offsetInBeginSection': 405, 'offsetInEndSection': 624, 'text': 'the CHARMS recommendations (Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies), extracting the information from its 11 domains (Source of data, Participants, etc). We determin', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33492724'}, {'offsetInBeginSection': 864, 'offsetInEndSection': 1020, 'text': 'acted the data. We used the Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS) checklist for the risk of ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35493941'}, {'offsetInBeginSection': 517, 'offsetInEndSection': 764, 'text': 'ical appraisal and data extraction for systematic reviews of prediction modeling studies (CHARMS) and the prediction model risk of bias assessment tool (PROBAST) were used for the data extraction process and critical appraisal.RESULTS: From the 29', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33364802'}, {'offsetInBeginSection': 461, 'offsetInEndSection': 821, 'text': 'nalysed (domains of CHARMS, Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies) the following: source of data, participants, outcome to be predicted, candidate predictors, sample size, missing data, model development, model performance, model evaluation, results and interpretation and discussion.RESULTS: We found tw', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31441567'}]\n\n\n                 'What is CHARMS with respect to medical review of predictive modeling?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS).\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 75, 'text': 'Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35939578'}, {'offsetInBeginSection': 193, 'offsetInEndSection': 406, 'text': 'Whether treatment with litifilimab, a humanized monoclonal antibody against BDCA2, would be efficacious in reducing disease activity in patients with cutaneous lupus erythematosus has not been extensively studied.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35939578'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 74, 'text': 'Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36069871'}, {'offsetInBeginSection': 258, 'offsetInEndSection': 420, 'text': ' The safety and efficacy of subcutaneous litifilimab, a humanized monoclonal antibody that binds to BDCA2, in patients with SLE have not been extensively studied.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36069871'}]\n\n\n                 'What is the target of Litifilimab?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"BDCA2\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 847, 'offsetInEndSection': 915, 'text': '. The area under the receiver operator characteristics curve (AUROC)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35610482'}, {'offsetInBeginSection': 1513, 'offsetInEndSection': 1556, 'text': 'area under receiver operator curve [AUROC] ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35426141'}, {'offsetInBeginSection': 819, 'offsetInEndSection': 927, 'text': 'The model performance was evaluated using the area under the receiver operating characteristic curve (AUROC)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35438215'}, {'offsetInBeginSection': 478, 'offsetInEndSection': 672, 'text': 'Our models predict GDM with high accuracy even at pregnancy initiation (area under the receiver operating curve (auROC)\\u2009=\\u20090.85), substantially outperforming a baseline risk score (auROC\\u2009=\\u20090.68).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31932807'}, {'offsetInBeginSection': 858, 'offsetInEndSection': 1147, 'text': ' prediction of pancreatic cancer. Two popular models were evaluated: logistic regression and a recurrent neural network.RESULTS: For logistic regression, using UMLS delivered the optimal area under the receiver operating characteristics (AUROC) results in both dengue hemorrhagic fever (81', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32930711'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 102, 'text': 'Area under the receiver operating characteristics (AUROC) curve is often used to evaluate risk models.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21958955'}, {'offsetInBeginSection': 117, 'offsetInEndSection': 271, 'text': 'stic tests. Rather, researchers use the area under the receiver operating characteristic (AUROC) as the key metric to gauge and report predictive performa', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31093546'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 175, 'text': 'Area under a receiver-operating-characteristic (AUROC) curve is widely used in medicine to summarize the ability of a continuous predictive marker to predict a binary outcome.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28860560'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 258, 'text': 'The c statistic, or area under the receiver operating characteristic (ROC) curve, achieved popularity in diagnostic testing, in which the test characteristics of sensitivity and specificity are relevant to discriminating diseased versus nondiseased patients.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17309939'}, {'offsetInBeginSection': 1598, 'offsetInEndSection': 1949, 'text': '-day mortality, respectively. When using only baseline variables to predict mortality, all algorithms except SVM (area under the receiver operator characteristic curve [AUROC], 0.83 [95% confidence interval {CI}, 0.69-0.97]) had AUROC >0.9: GBM (AUROC, 0.96 [0.94-1.0]), RF (AUROC, 0.96 [0.92-1.0]), CNN (AUROC, 0.96 [0.92-0.99]), and logistic regress', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34908548'}, {'offsetInBeginSection': 99, 'offsetInEndSection': 361, 'text': 'We assessed model performance using two metrics, the area under the receiver operating characteristic curve (AUROC) and the area under the precision-recall curve (AUPRC), to illustrate the differences in information they convey in the setting of class imbalance.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31437918'}, {'offsetInBeginSection': 777, 'offsetInEndSection': 958, 'text': 'The two approaches were explored and validated within the context of mRNA expression level prediction and have the area under the ROC curve (auROC) values ranging from 0.75 to 0.94.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30842277'}, {'offsetInBeginSection': 862, 'offsetInEndSection': 1132, 'text': '.4%) and validation (47.4%) cohorts. The FibroGENE-DT yielded the area under the receiver operating characteristic curve (AUROCs) of 0.87, 0.85 and 0.804 for the prediction of fast fibrosis progression, cirrhosis and significant fibrosis risk, respectively, with compara', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26592354'}, {'offsetInBeginSection': 1711, 'offsetInEndSection': 1952, 'text': 'ement (oral or IV) was 41.1%. Independent predictors using history alone were female sex, decreasing age, surgical history, and non-Caucasian ethnicity (model area under the receiver operating characteristic curve [AUROC], 0.59 [95% confiden', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31094792'}, {'offsetInBeginSection': 808, 'offsetInEndSection': 1084, 'text': ' reduction of at least I\u00b0 MR. One-year mortality was 28.2%.In Kaplan-Meier analysis, one- year mortality was significantly higher in RVD-pts (34.8% vs 2.8%, p\\xa0=\\xa00.009).Area under the Receiver Operating Characteristic (AUROC) for SHFM and MAGGIC were comparable for both scores', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33088899'}, {'offsetInBeginSection': 1371, 'offsetInEndSection': 1584, 'text': 'Using a standard multivariate approach to combine predictors, the PPIN model achieved an AUROC (area under the receiver operating characteristic curve) of 0.81 with a sensitivity of 48% given a specificity of 90%.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23620757'}, {'offsetInBeginSection': 360, 'offsetInEndSection': 510, 'text': 'cognitive impairment was evaluated using area under the receiver operating characteristic curve (AUROC), and multivariate logistic regression was appl', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35879562'}, {'offsetInBeginSection': 1005, 'offsetInEndSection': 1155, 'text': 'ssion, using UMLS delivered the optimal area under the receiver operating characteristics (AUROC) results in both dengue hemorrhagic fever (81.15%) an', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32930711'}, {'offsetInBeginSection': 1325, 'offsetInEndSection': 1475, 'text': 's). Sensitivity, specificity, predictive values and area under receiving operating curves (AUROC) of RBUS for VCUG abnormalities were determined.RESUL', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25958031'}, {'offsetInBeginSection': 598, 'offsetInEndSection': 748, 'text': 'ys). Model performance was assessed using area under the receiver operator characteristic curve (AUROC). Pre-N8-GP prophylaxis models learned from dat', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34865209'}, {'offsetInBeginSection': 536, 'offsetInEndSection': 686, 'text': 'agnostic threshold were evaluated using area under the receiver operating characteristic curve (AUROC). Stratification analysis by age and MP-IgM tite', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34154565'}, {'offsetInBeginSection': 543, 'offsetInEndSection': 693, 'text': ' learning algorithms was assessed by the area under the receiver operating characteristic curve (AUROC). The conventional scoring models had various p', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35505048'}, {'offsetInBeginSection': 471, 'offsetInEndSection': 621, 'text': 'sing PubMed, MEDLINE, and Scopus databases. Papers with area under the receiver operating curve (AUROC) scores reported were included in the analysis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33203588'}, {'offsetInBeginSection': 837, 'offsetInEndSection': 987, 'text': 'nstruct the prediction model. Finally, the area under the receiver operating characteristic (AUROC) curve was used to compare the model performance.RE', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36329470'}, {'offsetInBeginSection': 1029, 'offsetInEndSection': 1179, 'text': 'cy for tasks such as predicting: in-hospital mortality (area under the receiver operator curve [AUROC] across sites 0.93-0.94), 30-day unplanned readm', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31304302'}, {'offsetInBeginSection': 112, 'offsetInEndSection': 262, 'text': 'rognostic tests. Rather, researchers use the area under the receiver operating characteristic (AUROC) as the key metric to gauge and report predictive', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31093546'}, {'offsetInBeginSection': 1005, 'offsetInEndSection': 1216, 'text': 'ssion, using UMLS delivered the optimal area under the receiver operating characteristics (AUROC) results in both dengue hemorrhagic fever (81.15%) and pancreatic cancer (80.53%) tasks. For recurrent neural netw', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32930711'}, {'offsetInBeginSection': 1325, 'offsetInEndSection': 1466, 'text': 's). Sensitivity, specificity, predictive values and area under receiving operating curves (AUROC) of RBUS for VCUG abnormalities were determi', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25958031'}, {'offsetInBeginSection': 471, 'offsetInEndSection': 577, 'text': 'sing PubMed, MEDLINE, and Scopus databases. Papers with area under the receiver operating curve (AUROC) sc', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33203588'}, {'offsetInBeginSection': 837, 'offsetInEndSection': 955, 'text': 'nstruct the prediction model. Finally, the area under the receiver operating characteristic (AUROC) curve was used to ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36329470'}, {'offsetInBeginSection': 112, 'offsetInEndSection': 266, 'text': 'rognostic tests. Rather, researchers use the area under the receiver operating characteristic (AUROC) as the key metric to gauge and report predictive per', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31093546'}, {'offsetInBeginSection': 360, 'offsetInEndSection': 706, 'text': 'cognitive impairment was evaluated using area under the receiver operating characteristic curve (AUROC), and multivariate logistic regression was applied to evaluate predictive accuracy of biomarkers on cognitive impairment; 178 subjects (41 PD, 31 VaD and 106 normal controls) were included. In multiple linear regression analysis of PD patients', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35879562'}, {'offsetInBeginSection': 652, 'offsetInEndSection': 945, 'text': 'of outcome (AC), sensitivity (SN), specificity (SP), and area under receiver-operating curve (AUROC) were compared between 3 models: KCC (INR, creatinine, coma grade, pH), CART analysis using only KCC variables (KCC-CART) and a CART model using new variables (NEW-CART).RESULTS: Traditional KC', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25885260'}, {'offsetInBeginSection': 652, 'offsetInEndSection': 941, 'text': 'models of the EGFR mutation status (Model 1: area under the receiver operating characteristic curve [AUROC]\\u2009=\\u20090.910, 95% CI 0.861-0.945; Model 2: AUROC\\u2009=\\u20090.859, 95% CI 0.803-0.904; Model 3: AUROC\\u2009=\\u20090.711, 95% CI 0.643-0.773). A testing set (n\\u2009=\\u200950) and temporal validation data set (n\\u2009=\\u200970', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31807867'}, {'offsetInBeginSection': 1029, 'offsetInEndSection': 1371, 'text': \"cy for tasks such as predicting: in-hospital mortality (area under the receiver operator curve [AUROC] across sites 0.93-0.94), 30-day unplanned readmission (AUROC 0.75-0.76), prolonged length of stay (AUROC 0.85-0.86), and all of a patient's final discharge diagnoses (frequency-weighted AUROC 0.90). These models outperformed traditional, c\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31304302'}, {'offsetInBeginSection': 838, 'offsetInEndSection': 1056, 'text': ' matrix, accuracy, precision, recall, F1 score, and Area under the\\xa0Receiver Operating Characteristics (AUROC) were used to evaluate the performance of predictive models.RESULTS: Ability of prediction was between 68.6% ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35509018'}, {'offsetInBeginSection': 846, 'offsetInEndSection': 1064, 'text': ' accuracy, precision, recall, F1 score, and Area under the\\xa0Receiver Operating Characteristics (AUROC) were used to evaluate the performance of predictive models.RESULTS: Ability of prediction was between 68.6% and 61.5', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35509018'}, {'offsetInBeginSection': 1023, 'offsetInEndSection': 1173, 'text': 's), positive predictive values (PPVs), and area under the receiver operating characteristic curve (AUROC), of machine learning models when predicting ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31509205'}, {'offsetInBeginSection': 645, 'offsetInEndSection': 838, 'text': 'ance of prediction, accuracy of discrimination (area under the receiver operating characteristic curve [AUROC]), calibration, and validity of the two predictive models were investigated. The co', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28323524'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 734, 'text': 'The area under the receiver operating characteristic (ROC) curve (AUC) is commonly used for assessing the discriminative ability of prediction models even though the measure is criticized for being clinically irrelevant and lacking an intuitive interpretation. Every tutorial explains how the coordinates of the ROC curve are obtained from the risk distributions of diseased and non-diseased individuals, but it has not become common sense that therewith the ROC plot is just another way of presenting these risk distributions. We show how the ROC curve is an alternative way to present risk distributions of diseased and non-diseased individuals and how the shape of the ROC curve informs about the overlap of the risk distributions.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31967640'}]\n\n\n                 'What is AUROC in context of predictive modeling?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"area under the receiver operator characteristics curve\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 713, 'text': 'On October 24, 2016, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda; Merck & Co., Inc., https://www.merck.com) for treatment of patients with metastatic non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1) as determined by an FDA-approved test, as follows: (a) first-line treatment of patients with mNSCLC whose tumors have high PD-L1 expression (tumor proportion score [TPS] \u226550%), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations, and (b) treatment of patients with mNSCLC whose tumors express PD-L1 (TPS \u22651%), with disease progression on or after platinum-containing chemotherapy. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28835513'}]\n\n\n                 'When was Keytruda approved by the FDA for the treatment of metastatic non-small cell lung cancer?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"October 24, 2016\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 1548, 'offsetInEndSection': 1645, 'text': 'We estimated reduced time and costs by online counseling with about 8% and 10-12%, respectively. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26785833'}]\n\n\n                 'What is the estimated reduction in time when using online genetic counseling?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"8%\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 712, 'text': 'On October 24, 2016, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda; Merck & Co., Inc., https://www.merck.com) for treatment of patients with metastatic non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1) as determined by an FDA-approved test, as follows: (a) first-line treatment of patients with mNSCLC whose tumors have high PD-L1 expression (tumor proportion score [TPS] \u226550%), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations, and (b) treatment of patients with mNSCLC whose tumors express PD-L1 (TPS \u22651%), with disease progression on or after platinum-containing chemotherapy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28835513'}]\n\n\n                 'Which company produces Keytruda?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Merck & Co., Inc.\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 128, 'offsetInEndSection': 195, 'text': 'Cereblon is a well-known target of thalidomide and its derivatives.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36252444'}, {'offsetInBeginSection': 399, 'offsetInEndSection': 580, 'text': 'We have identified novel CRBN inhibitors, namely DHFO and its analogs, with structural features that are slightly different from thalidomide but stronger cereblon-binding affinity. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36252444'}, {'offsetInBeginSection': 98, 'offsetInEndSection': 338, 'text': ' It additionally modulates the anti-myeloma effect of the immunomodulatory drugs (IMiDs) thalidomide, lenalidomide, and pomalidomide. IMiDs bind to CRBN and recruit neo-substrates for their ubiquitination and proteasome-mediated degradation', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35045330'}, {'offsetInBeginSection': 162, 'offsetInEndSection': 443, 'text': '. Cereblon (CRBN)-targeting immunomodulatory agents (IMiDs\u00ae) lenalidomide (LEN) and pomalidomide (POM) play a central role in combination regimens due to their pleiotropic antitumor/immunomodulatory mechanisms that synergize with many anti-myeloma approved or developmental agents.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34316334'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 293, 'text': 'Thalidomide, well known for its potent teratogenicity, has been re-evaluated as a clinically effective drug for the treatment of multiple myeloma. Although the direct target of thalidomide had been unclear until recently, we identified cereblon (CRBN) as a primary direct target of this drug b', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31202702'}, {'offsetInBeginSection': 815, 'offsetInEndSection': 1076, 'text': 'The molecular mechanism of action of IMiDs remained unclear for a long time until 2010 when the protein cereblon (CRBN) was identified as a primary direct target. IMiDs binds to CRBN and alters the substrate specificity of the CRBN E3 ubiquitin ligase complex, ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31187860'}, {'offsetInBeginSection': 974, 'offsetInEndSection': 1307, 'text': 'These results strongly suggest that increased BK channel activity is the pathological mechanism of intellectual disability in CRBN mutations.SIGNIFICANCE STATEMENTCereblon (CRBN), a well known target of the immunomodulatory drug thalidomide, was originally identified as a gene that causes human intellectual disability when mutated.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29530986'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 123, 'text': 'Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22552008'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 208, 'text': 'Cereblon (CRBN), a substrate receptor for the cullin-RING ubiquitin ligase 4 (CRL4) complex, is a direct protein target for thalidomide teratogenicity and antitumor activity of immunomodulatory drugs (IMiDs).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26990986'}, {'offsetInBeginSection': 1246, 'offsetInEndSection': 1409, 'text': 'Our biophysical, biochemical and gene silencing studies show that CRBN is a proximate, therapeutically important molecular target of lenalidomide and pomalidomide.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22552008'}, {'offsetInBeginSection': 586, 'offsetInEndSection': 899, 'text': 'CRBN has been identified as a direct target for immunomodulatory drugs (IMiD) and plays a significant role in anti-proliferation, pro-apoptotic effects, anti-angiogenic activities, immunomodulatory activities and intervention of cell surface adhesion molecules between myeloma cells and bone marrow stromal cells.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26117057'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 265, 'text': 'Thalidomide and its derivatives lenalidomide and\\xa0pomalidomide, known as immunomodulatory drugs, (IMiDs)\\xa0bind\\xa0directly to cereblon (CRBN), a substrate receptor of an E3 ubiquitin ligase, resulting in the rapid ubiquitination and degradation of the substrate protein.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33938033'}, {'offsetInBeginSection': 268, 'offsetInEndSection': 321, 'text': 'Cereblon (CRBN) is a common primary target for IMiDs.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28978850'}, {'offsetInBeginSection': 241, 'offsetInEndSection': 397, 'text': 'Cereblon (CRBN), a substrate receptor of the CRL4 ubiquitin ligase complex, is the primary target by which IMiDs mediate anticancer and teratogenic effects.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27294876'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 161, 'text': 'Cereblon (CRBN) has recently been identified as a target for immunomodulatory drugs (IMiDs) and its downregulation has been linked to resistance to lenalidomide.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23565715'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 138, 'text': 'Cereblon (CRBN), originally identified as a gene associated with intellectual disability, was identified as primary target of thalidomide.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34033753'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 270, 'text': 'Clinical interest in the measurement of Cereblon (CRBN), the primary target of the IMiDs immunomodulatory drugs lenalidomide and pomalidomide, has been fueled by its essential requirement for antitumor or immunomodulatory activity of both drugs in multiple myeloma (MM).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26186254'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 133, 'text': 'Cereblon (CRBN), a substrate receptor for Cullin-ring E3 ubiquitin ligase (CRL), is a major target protein of immunomodulatory drugs.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32333926'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 162, 'text': 'Cereblon (CRBN), a substrate receptor of the Cullin 4 RING E3 ubiquitin ligase complex, is the target of the immunomodulatory drugs lenalidomide and pomalidomide.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26002965'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 240, 'text': 'Cereblon was identified as a direct target of thalidomide by Prof. H. Handa, and this pioneering work triggered active research on IMiDs (immunomodulatory drugs), which include thalidomide-derivatives, such as lenalidomide and pomalidomide.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25626321'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 169, 'text': 'The Cullin-RING ligase 4 E3 ubiquitin ligase component Cereblon (CRBN) is a well-established target for a class of small molecules termed immunomodulatory drugs (IMiDs).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35780831'}, {'offsetInBeginSection': 636, 'offsetInEndSection': 750, 'text': ' We identified a thalidomide-binding protein, cereblon (CRBN), as a primary target for thalidomide teratogenicity.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21207098'}, {'offsetInBeginSection': 359, 'offsetInEndSection': 567, 'text': ' Although the direct target of thalidomide was largely debated until recently, our groups discovered cereblon (CRBN), a substrate receptor of an E3 ubiquitin ligase as a primary target of thalidomide in 2010.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35831190'}, {'offsetInBeginSection': 267, 'offsetInEndSection': 321, 'text': ' Cereblon (CRBN) is a common primary target for IMiDs.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28978850'}, {'offsetInBeginSection': 172, 'offsetInEndSection': 322, 'text': 'd previously demonstrated that cereblon (CRBN) is the target of thalidomide embryopathy and acts as a substrate receptor for the E3 ubiquitin ligase c', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33777938'}, {'offsetInBeginSection': 333, 'offsetInEndSection': 483, 'text': 'dy recently identified cereblon (CRBN) as a primary target of thalidomide teratogenicity. Subsequently it was demonstrated that CRBN is also required ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22966948'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'Cereblon (CRBN) has recently been identified as a target for immunomodulatory drugs (IMiDs) and its downregulation has been linked to resistance to le', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23565715'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'Cereblon (CRBN), the molecular target of lenalidomide and pomalidomide, is a substrate receptor of the cullin ring E3 ubiquitin ligase complex, CRL4(C', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24328678'}, {'offsetInBeginSection': 163, 'offsetInEndSection': 313, 'text': 'eblon (CRBN) has been identified as the primary teratogenic target of thalidomide. Our studies demonstrate that thalidomide, lenalidomide and another ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22552008'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 156, 'text': 'Cereblon (CRBN), the molecular target of lenalidomide and pomalidomide, is a substrate receptor of the cullin ring E3 ubiquitin ligase complex, CRL4(CRBN) .', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24328678'}, {'offsetInBeginSection': 242, 'offsetInEndSection': 392, 'text': 'cluding multiple myeloma. Cereblon (CRBN) is a common primary target for IMiDs. It works as a substrate receptor of CRL4. Accumulating evidence has sh', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28978850'}, {'offsetInBeginSection': 92, 'offsetInEndSection': 242, 'text': 'ubiquitin ligase complex component. Cereblon is a well-known target of thalidomide and its derivatives. Cereblon is involved in multiple myeloma cell ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36252444'}]\n\n\n                 'Cereblon (CRBN)  has been identified as the target for what type of drug?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Immunomodulatory drugs (IMiDs)\", \"Thalidomide\", \"pomalidomide\", \"lenalidomide\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 241, 'text': \"Dermatillomania or skin picking disorder (SPD) is a chronic, recurrent, and treatment resistant neuropsychiatric disorder with an underestimated prevalence that has a concerning negative impact on an individual's health and quality of life. \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33808008'}]\n\n\n                 'What is the difference between dermatillomania and skin picking disorder?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"None\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 189, 'text': 'Non-pathogenic Rickettsia species LON strains closely related to an agent of Japanese spotted fever (JSF), R. japonica, were isolated in Japan from Haemaphysalis longicornis ticks in 2001. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32863353'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 221, 'text': 'Severe fever with thrombocytopenia syndrome (SFTS) and Japanese spotted fever (JSF; a spotted fever group rickettsiosis) are tick-borne zoonoses that are becoming a significant public health threat in Japan and East Asia.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36016429'}, {'offsetInBeginSection': 153, 'offsetInEndSection': 288, 'text': 'Rickettsia japonica is a member of SFG rickettsiae causing Japanese spotted fever (JSF) and can transmit to humans via infected ticks. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35507925'}]\n\n\n                 'What causes Japanese Spotted Fever?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Rickettsia japonica\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 240, 'text': 'Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34344706'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 154, 'text': 'OBJECTIVE: To evaluate the efficacy and safety of olokizumab (OKZ) in patients with active rheumatoid arthritis despite treatment with methotrexate (MTX).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34344706'}, {'offsetInBeginSection': 1387, 'offsetInEndSection': 1586, 'text': 'CONCLUSIONS: Treatment with OKZ was associated with significant improvement in signs, symptoms and physical function of rheumatoid arthritis without discernible differences between the two regimens. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34344706'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 64, 'text': 'Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36001712'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 245, 'text': 'BACKGROUND: The cytokine interleukin-6 is involved in the pathogenesis of rheumatoid arthritis. Olokizumab, a humanized monoclonal antibody targeting the interleukin-6 cytokine directly, is being tested for the treatment of rheumatoid arthritis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36001712'}, {'offsetInBeginSection': 2389, 'offsetInEndSection': 2722, 'text': 'CONCLUSIONS: In patients with rheumatoid arthritis who were receiving maintenance methotrexate, olokizumab was superior to placebo and noninferior to adalimumab in producing an ACR20 response at 12 weeks. Larger and longer trials are required to determine the efficacy and safety of olokizumab in patients with rheumatoid arthritis. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36001712'}]\n\n\n                 'Olokizumab is tested for which disease?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"rheumatoid arthritis\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 91, 'text': 'Structural and Mechanistic Bases of Viral Resistance to HIV-1 Capsid Inhibitor Lenacapavir.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36190128'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 79, 'text': 'Lenacapavir (LEN) is a long-acting, highly potent HIV-1 capsid (CA) inhibitor. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36190128'}, {'offsetInBeginSection': 803, 'offsetInEndSection': 1012, 'text': 'The investigational drug lenacapavir accesses unoccupied hydrophobic pockets in the complex to potently impair HIV-1 inside the nucleus without displacing the tightly bound cellular cofactor from virus cores. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36202818'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 145, 'text': 'Lenacapavir (Sunlenca\u00ae) is a long-acting capsid inhibitor of human immunodeficiency virus type\\xa01 (HIV-1) being developed by Gilead Sciences Inc. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36272024'}, {'offsetInBeginSection': 301, 'offsetInEndSection': 696, 'text': 'In August 2022, lenacapavir received its first approval in the EU for use in combination with other antiretroviral(s) in adults with multi-drug resistant HIV infection, for whom it is otherwise not possible to construct a suppressive anti-viral regimen. This article summarizes the milestones in the development of lenacapavir leading to this first approval for the treatment of HIV-1 infection.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36272024'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 53, 'text': 'Lenacapavir: a first-in-class HIV-1 capsid inhibitor.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34871187'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 496, 'text': 'PURPOSE OF REVIEW: This review summarizes available data for lenacapavir, an investigational first-in-class agent that disrupts functioning of HIV capsid protein across multiple steps in the viral life cycle.RECENT FINDINGS: Lenacapavir demonstrated picomolar potency in vitro with no cross resistance to existing antiretroviral classes and potent antiviral activity in persons with HIV-1. In persons with HIV-1, there was no preexisting resistance to lenacapavir regardless of treatment history.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34871187'}, {'offsetInBeginSection': 600, 'offsetInEndSection': 1015, 'text': 'In heavily treatment-experienced persons with multidrug-resistant HIV-1 and in treatment-naive persons with HIV-1, lenacapavir in combination with other antiretroviral agents led to high rates of virologic suppression and was well tolerated.SUMMARY: Ongoing studies are evaluating long-acting dosing of lenacapavir for treating HIV-1 in combination with other antiretrovirals and preventing HIV-1 as a single agent.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34871187'}]\n\n\n                 'What disease can be treated with Lenacapavir?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"HIV-1\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 129, 'text': 'Mantle cell lymphoma (MCL) is a relatively rare B-cell non-Hodgkin lymphoma, typically presenting with extensive lymphadenopathy,', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32774275'}, {'offsetInBeginSection': 207, 'offsetInEndSection': 483, 'text': 'Activity has been demonstrated in many subtypes of B-cell lymphoma, including diffuse large cell lymphoma, follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), lymphocyte-predominant Hodgkin lymphoma, and Waldenstr\u00f6m macroglobulinemia (WM)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28203581'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 102, 'text': \"Mantle cell lymphoma (MCL) is a subtype of B-cell non-Hodgkin's lymphoma seen predominantly in males. \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26604506'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 189, 'text': 'Mantle cell lymphoma is an aggressive, non-curable B-cell lymphoma, characterized by the translocation t(11;14)(q13;q32) involving CCND1 and a high number of additional genetic alterations.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22555177'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 126, 'text': \"Mantle cell lymphoma (MCL) is a B cell non-Hodgkin's lymphoma, characterized by a poor response to therapy and short survival.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10942246'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 173, 'text': 'Mantle cell lymphoma is a B cell lymphoproliferative disorder cytogenetically characterized by the t(11;14)(q13;q32) which at molecular level involves the Bcl-1/PRAD-1 gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8649059'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 131, 'text': 'BACKGROUND: Mantle zone lymphoma (MZL) is a B-cell proliferation regarded as the follicular variant of intermediate lymphocytic lym', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8277026'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'BACKGROUND: Mantle cell lymphoma is a mature, virgin B-cell neoplasm characterized immunologically by a panB+, CD5+, CD23-, cyclin D1+ phenotype and g', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10463985'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 231, 'text': 'BACKGROUND: Mantle cell lymphoma is a mature, virgin B-cell neoplasm characterized immunologically by a panB+, CD5+, CD23-, cyclin D1+ phenotype and genetically by t(11;14)(q13;q32) with overexpression of the cyclin D1 (bcl-1) gene', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10463985'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 286, 'text': 'Mantle cell lymphoma (MCL) is a unique subtype of B-cell non-Hodgkin lymphoma with a generally aggressive and heterogeneous clinical course. Chemokines are one of the complex components in the tumor microenvironment (TME), and they play a vital role in tumor progression and metastasis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33197439'}]\n\n\n                 'What cells proliferate in Mantle Cell Lymphoma'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"B cells\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 1548, 'offsetInEndSection': 1644, 'text': 'We estimated reduced time and costs by online counseling with about 8% and 10-12%, respectively.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26785833'}]\n\n\n                 'What is the estimated cost reduction when using telegenetics?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"10-12%\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 181, 'offsetInEndSection': 402, 'text': 'METHODS: In this phase 2, double-blind, placebo-controlled trial, we investigated the efficacy and safety of BI 1015550, an oral preferential inhibitor of the PDE4B subtype, in patients with idiopathic pulmonary fibrosis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35569036'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 143, 'text': 'Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36299369'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 101, 'text': 'Introduction: BI 1015550 is a phosphodiesterase 4 (PDE4) inhibitor that has antifibrotic properties. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36299369'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 118, 'text': 'BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35517783'}, {'offsetInBeginSection': 351, 'offsetInEndSection': 441, 'text': 'BI 1015550 is a novel PDE4 inhibitor showing a preferential enzymatic inhibition of PDE4B.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35517783'}, {'offsetInBeginSection': 2098, 'offsetInEndSection': 2401, 'text': 'In summary, the unique preferential inhibition of PDE4B by BI 1015550 and its anticipated improved tolerability in humans, plus its anti-inflammatory and antifibrotic potential, suggest BI 1015550 to be a promising oral clinical candidate for the treatment of IPF and other fibro-proliferative diseases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35517783'}]\n\n\n                 'What is the target of BI 1015550?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"phosphodiesterase 4B\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 393, 'text': 'Recessive dystrophic epidermolysis bullosa (RDEB) is a lifelong genodermatosis associated with blistering, wounding, and scarring caused by mutations in COL7A1, the gene encoding the anchoring fibril component, collagen VII (C7). Here, we evaluated beremagene geperpavec (B-VEC), an engineered, non-replicating COL7A1 containing herpes simplex virus type 1 (HSV-1) vector, to treat RDEB skin. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35347281'}, {'offsetInBeginSection': 1370, 'offsetInEndSection': 1528, 'text': 'These studies show that B-VEC is an easily administered, safely tolerated, topical molecular corrective therapy promoting wound healing in patients with RDEB.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35347281'}]\n\n\n                 'Beremagene Geperpavec is tested for which disease?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"recessive dystrophic epidermolysis bullosa\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 212, 'text': '\"Hairpatches\" (Hpt) is a naturally occurring, autosomal semi-dominant mouse mutation. Hpt/Hpt homozygotes die in utero, while Hpt/+ heterozygotes exhibit progressive renal failure accompanied by patchy alopecia. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23301070'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 171, 'text': 'Hairpatches, a single gene mutation characterized by progressive renal disease and alopecia in the mouse. A potential model for a newly described heritable human disorder.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1836514'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 167, 'text': 'Retrotransposon insertion in the T-cell acute lymphocytic leukemia 1 (Tal1) gene is associated with severe renal disease and patchy alopecia in Hairpatches (Hpt) mice.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23301070'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 105, 'text': 'Hairpatches, a single gene mutation characterized by progressive renal disease and alopecia in the mouse.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1836514'}]\n\n\n                 'Hairpatches is a single gene mutation associated with what disease?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"alopecia and renal failure\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 107, 'text': 'Alternative splicing of HSPA12A pre-RNA by SRSF11 contributes to metastasis potential of colorectal cancer.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36394206'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 102, 'text': 'Alternative microexon splicing by RBFOX2 and PTBP1 is associated with metastasis in colorectal cancer.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34346508'}, {'offsetInBeginSection': 638, 'offsetInEndSection': 1073, 'text': 'RNA interference-mediated knockdown experiments identified two splicing factors, RBFOX2 and PTBP1, as regulators of microexon splicing in CRC cells. RBFOX2 and PTBP1 were found to directly bind to microexon-containing pre-mRNAs and to control their splicing in such cells. Differential microexon splicing was shown to be due, at least in part, to altered expression of RBFOX2 and PTBP1 in CRC tissue compared to matched normal tissue. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34346508'}, {'offsetInBeginSection': 1178, 'offsetInEndSection': 1320, 'text': 'Our data thus suggest that altered expression of RBFOX2 and PTBP1 might influence CRC metastasis through the regulation of microexon splicing.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34346508'}]\n\n\n                 'What is the alternative microexon splicing by RBFOX2 and PTBP1 associated with?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"colorectal cancer metastasis\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 102, 'text': 'Cribriform Appearance of White Matter in Canavan Disease Associated with Novel Mutations of ASPA Gene.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36267868'}, {'offsetInBeginSection': 652, 'offsetInEndSection': 837, 'text': 'Genetic analysis revealed novel mutations in the aspartoacylase or ASPA gene that possibly accounts for the severe form of Canavan disease, which probably explains the imaging findings.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36267868'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 121, 'text': 'Canavan disease (CD) is an inherited leukodystrophy resulting from mutations in the gene encoding aspartoacylase (ASPA). ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35636725'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 290, 'text': 'Canavan disease (CD) is a devastating neurological disease that lacks effective therapy. Because CD is caused by mutations of the aspartoacylase (ASPA) gene, we introduced the wild-type (WT) ASPA gene into patient iPSCs through lentiviral transduction or CRISPR/Cas9-mediated gene editing. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35637731'}, {'offsetInBeginSection': 1284, 'offsetInEndSection': 1453, 'text': 'The compound heterozygous variants of the ASPA gene probably underlay the Canavan disease in this patient, and the result has enabled prenatal diagnosis for this family.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35929936'}]\n\n\n                 'Which gene is implicated in Canavan disease?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"ASPA\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 78, 'text': 'Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35626120'}, {'offsetInBeginSection': 361, 'offsetInEndSection': 624, 'text': 'In this study, we evaluated the safety and efficacy of a monotherapy with the bispecific CD20xCD3 antibody glofitamab in patients who progressed after CAR T treatment. We report nine consecutive patients with progressive DLBCL after preceding CAR T-cell therapy. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35626120'}, {'offsetInBeginSection': 1106, 'offsetInEndSection': 1284, 'text': 'Our data suggest that glofitamab treatment is well tolerated and effective in patients with DLBCL relapsing after CAR T-cell therapy and can enhance residual CAR T-cell activity.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35626120'}, {'offsetInBeginSection': 674, 'offsetInEndSection': 976, 'text': 'Bispecific antibodies such as epcoritamab, mosunetuzumab, and glofitamab, anti-CD19 antibody drug tafasitamab combined with lenalidomide, CD19 antibody drug conjugate loncastuximab tesirine, oral selective inhibitor of nuclear export selinexor, and several new agents have been investigated for DLBCL. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36198538'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 200, 'text': 'Glofitamab, a novel CD20xCD3, T-cell-engaging bispecific antibody, exhibited single-agent activity in Study NP30179, a first-in-human, phase 1 trial in relapsed/refractory B-cell non-Hodgkin lymphoma.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34941996'}]\n\n\n                 'What disease can be treated with Glofitamab?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"DLBCL\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 711, 'offsetInEndSection': 1109, 'text': 'Recent results from the PEACHTREE trial (ClinicalTrials.gov Identifier: NCT02595398), a phase III trial with two suprachoroidal injections of CLS-TA at 0 and 12 weeks with follow up lasting 24 weeks, showed the significant improvement in visual acuity and reduction in central subfield thickness, all without increasing the risk of elevated intraocular pressure or accelerated cataract progression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34322164'}]\n\n\n                 'How many injections of CLS-TA did the patients participating in the PEACHTREE trial receive?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"two\", \"2\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 204, 'text': 'Prosopagnosia is the inability to recognize someone by the face alone in the absence of sensory or intellectual impairment. In contrast to the acquired form of prosopagnosia we studied the congenital form', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16767465'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 242, 'text': 'Congenital prosopagnosia (cPA) is a selective impairment in the visual learning and recognition of faces without detectable brain damage or malformation. There is evidence that it can be inherited in an autosomal dominant mode of inheritance.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19429021'}, {'offsetInBeginSection': 134, 'offsetInEndSection': 286, 'text': 'Here we report a follow-up examination on M.T., suffering from acquired prosopagnosia following a large unilateral right-hemispheric lesion in frontal, ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36202621'}, {'offsetInBeginSection': 124, 'offsetInEndSection': 205, 'text': 'In contrast to the acquired form of prosopagnosia we studied the congenital form.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16767465'}, {'offsetInBeginSection': 67, 'offsetInEndSection': 257, 'text': 'Acquired prosopagnosia results after brain damage, developmental or congenital prosopagnosia (CP) is not caused by brain lesion, but has presumably been present from early childhood onwards.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19823580'}, {'offsetInBeginSection': 56, 'offsetInEndSection': 216, 'text': 'Acquired prosopagnosia is the loss of familiarity for facial identity and has several functional variants, namely apperceptive, amnestic, and associative forms.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33832676'}, {'offsetInBeginSection': 327, 'offsetInEndSection': 478, 'text': 'A selective deficit in the visual learning and recognition of faces is known as prosopagnosia, which can be found both in acquired and congenital form.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19334306'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 78, 'text': 'Congenital prosopagnosia--a common hereditary cognitive dysfunction in humans.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17981784'}, {'offsetInBeginSection': 921, 'offsetInEndSection': 1029, 'text': 'Thus, the face recognition impairment of the hereditary prosopagnosics is reflected in their gaze behaviour.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16767465'}, {'offsetInBeginSection': 684, 'offsetInEndSection': 846, 'text': 'Whereas the control participants focused their gaze on the central facial features, the hereditary prosopagnosics showed a significantly different gaze behaviour.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16767465'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 155, 'text': 'BACKGROUND: Prosopagnosia is a selective deficit in facial identification which can be either acquired, (e.g., after brain damage), or present from birth (', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20657764'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 142, 'text': 'Prosopagnosia is an impairment in the ability to recognize faces and can be acquired after a brain lesion or occur as a developmental variant.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31231507'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 121, 'text': 'Previous studies have shown that acquired prosopagnosia is characterized by impairment at holistic/configural processing.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21366884'}, {'offsetInBeginSection': 538, 'offsetInEndSection': 687, 'text': ' This served to investigate whether congenital prosopagnosia results from process-specific deficiencies, or whether it is a face-specific impairment.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20689639'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 81, 'text': 'Prosopagnosia refers to an acquired or developmental deficit in face recognition.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30389553'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 152, 'text': 'BACKGROUND: Congenital prosopagnosia is a severe face perception impairment which is not acquired by a brain lesion and is presumably present from birth', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18523592'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 225, 'text': 'Three patients with prosopagnosia, and acquired inability to recognize familiar faces usually resulting from cerebrovascular insufficiency, had left-sided visual field defects and color vision abnormalities of central origin.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7091286'}, {'offsetInBeginSection': 1042, 'offsetInEndSection': 1161, 'text': 'The segregation pattern of this hereditary prosopagnosia (HPA) is fully compatible with autosomal dominant inheritance.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16817175'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 195, 'text': 'A Quick guide to developmental prosopagnosia, a condition definied by problems in recognising faces that, in contrast with acquired prosopagnosia, develop in the absence of manifest brain injury.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27115682'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 166, 'text': 'BACKGROUND: Prosopagnosia is a selective deficit in facial identification which can be either acquired, (e.g., after brain damage), or present from birth (congenital)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20657764'}, {'offsetInBeginSection': 506, 'offsetInEndSection': 656, 'text': 'ing clinically significant impairments in facial recognition. Cases of acquired prosopagnosia were identified through a systematic literature search a', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31740940'}, {'offsetInBeginSection': 171, 'offsetInEndSection': 326, 'text': 'Reflecting this, acquired prosopagnosia is not a single entity but a family of disorders with different anatomic lesions and different functional deficits.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24389150'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 163, 'text': 'BACKGROUND: Acquired prosopagnosia is a rare condition characterized by the loss of familiarity with previously known faces and the inability to recognize new ones', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33392335'}, {'offsetInBeginSection': 545, 'offsetInEndSection': 930, 'text': 'Three key findings emerged: (a) Individuals with more severe prosopagnosia spent less time examining the internal facial region, (b) as observed in acquired prosopagnosia, some DPs spent less time examining the eyes and more time examining the mouth than controls, and (c) SRs spent more time examining the nose-a measure that also correlated with face recognition ability in controls.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26933872'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 167, 'text': 'Acquired prosopagnosia is usually a consequence of bilateral or right hemisphere lesions and is often associated with topographical disorientation and dyschromatopsia.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32648048'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'Prosopagnosia is a deficit in recognizing people from their faces. Acquired prosopagnosia results after brain damage, developmental or congenital pros', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19823580'}, {'offsetInBeginSection': 117, 'offsetInEndSection': 197, 'text': 'Cases of acquired prosopagnosia have often been described over the last century.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20689639'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 118, 'text': 'Acquired prosopagnosia is usually associated with bilateral or right-sided lesions of the occipital or temporal lobes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18374372'}, {'offsetInBeginSection': 640, 'offsetInEndSection': 864, 'text': 'Most subjects with developmental prosopagnosia were normal on the Old/New Tests: for acquired prosopagnosia, subjects with occipitotemporal lesions often showed impairments while those with anterior temporal lesions did not.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30947609'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 217, 'text': \"We studied a male with acquired prosopagnosia using a battery of Implicit Association Tests (IATs) to investigate whether observing faces varying by social category would activate the patient's implicit social biases.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21414330'}]\n\n\n                 'is prosopagnosia inherited or  acquired?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"both inherited and acquired\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 204, 'text': \"A promoter is a short region of DNA (100-1,000 bp) where transcription of a gene by RNA polymerase begins. It is typically located directly upstream or at the 5' end of the transcription initiation site. \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31750297'}, {'offsetInBeginSection': 274, 'offsetInEndSection': 369, 'text': 'Promoters mark the start of every transcript and are an important class of regulatory elements.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15899964'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 193, 'text': 'A promoter is a region in the DNA sequence that defines where the transcription of a gene by RNA polymerase initiates, which is typically located proximal to the transcription start site (TSS).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33227813'}, {'offsetInBeginSection': 107, 'offsetInEndSection': 203, 'text': \"It is typically located directly upstream or at the 5' end of the transcription initiation site.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31750297'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 176, 'text': 'A key step in the transcription of RNA is the binding of the RNA polymerase protein complex to a short promoter sequence that is typically upstream of the gene to be expressed.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36099980'}, {'offsetInBeginSection': 834, 'offsetInEndSection': 1023, 'text': 'Promoter regions are located within ~2\\xa0kb upstream of the transcriptional start site, whereas enhancers may be located at some distance from promoter sequences and exert long-range effects.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30414142'}, {'offsetInBeginSection': 111, 'offsetInEndSection': 245, 'text': 'These sequences are typically located in promoters, which are regions of variable length upstream of the open reading frames of genes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19258451'}, {'offsetInBeginSection': 674, 'offsetInEndSection': 857, 'text': 'Most of these promoters display the changes of DNA methylation in their Ups-regions, which are between +500 and +2000 bp upstream from the transcription start site (TSS) of the genes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25448745'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 130, 'text': 'Promoters are fundamental components of synthetic gene circuits. They are DNA segments where transcription initiation takes place.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34071849'}]\n\n\n                 'Where are promoters typically found in DNA?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Upstream of the coding region\", \"Directly upstream\", \"5' end of the transcription initiation site\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 711, 'offsetInEndSection': 1109, 'text': 'Recent results from the PEACHTREE trial (ClinicalTrials.gov Identifier: NCT02595398), a phase III trial with two suprachoroidal injections of CLS-TA at 0 and 12 weeks with follow up lasting 24 weeks, showed the significant improvement in visual acuity and reduction in central subfield thickness, all without increasing the risk of elevated intraocular pressure or accelerated cataract progression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34322164'}]\n\n\n                 'What was the duration of the follow-up period of patients in the PEACHTREE clinical trial?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"24 weeks\", \"6 months\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 513, 'text': 'Drug delivery to the suprachoroidal space (SCS\u00ae) has become a clinical reality after the 2021 FDA approval of CLS-TA, a triamcinolone acetonide injectable suspension for suprachoroidal use (XIPERE\u00ae), administered via a microneedle-based device, the SCS Microinjector\u00ae. Suprachoroidal (SC) delivery facilitates targeting, compartmentalization, and durability of small molecule suspensions, thereby potentially addressing some of the efficacy, safety, and treatment burden limitations of current retinal therapies. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35868358'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 101, 'text': 'Suprachoroidal delivery enables targeting, localization and durability of small molecule suspensions.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35868358'}]\n\n\n                 'What is the mode of delivery of the drug XIPERE?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"microneedle-based delivery in the suprachoroidal space\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 203, 'offsetInEndSection': 365, 'text': 'We explored the direct impact of T1AM on cardiomyocytes with a focus on the regulation of the intracellular temperature and natriuretic peptide (NP) expression. A', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35882940'}, {'offsetInBeginSection': 1458, 'offsetInEndSection': 1705, 'text': 'In hypertrophic cardiomyocytes, after up-regulating the expression of miR-145, the relative messenger ribonucleic acid (mRNA) and protein expressions of atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) induced by PE decreased.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35693619'}, {'offsetInBeginSection': 401, 'offsetInEndSection': 579, 'text': 'Stretching of cultured cardiomyocytes up-regulates the expression of brain natriuretic peptide (BNP). Intracellular calcium-elevating agents such as the calcium ionophore A23187,', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12732268'}, {'offsetInBeginSection': 460, 'offsetInEndSection': 571, 'text': 'Atrial natriuretic peptide (ANP) and brain (or B-type) natriuretic peptide (BNP) are of myocardial cell origin.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14574050'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 220, 'text': 'Brain (or B-type) natriuretic peptide (BNP) is a cardiac hormone produced in the heart and an established biochemical marker for heart failure (HF) because the level in plasma increases in proportion to disease severity.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30135320'}, {'offsetInBeginSection': 572, 'offsetInEndSection': 768, 'text': 'BNP is released mainly from the left ventricle in response to volume overload and has become the first biochemical marker for the identification of individuals with congestive heart failure (CHF).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14574050'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 268, 'text': 'BACKGROUND: B-type or brain natriuretic peptide (BNP) is a novel natriuretic peptide secreted from the heart that forms a peptide family with A-type or atrial natriuretic peptide (ANP), and its plasma level has been shown to be increased in patients with congestive he', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8025996'}, {'offsetInBeginSection': 174, 'offsetInEndSection': 335, 'text': 'Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are of myocardial cell origin and C-type natriuretic peptide (CNP) is of endothelial origin.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10519161'}, {'offsetInBeginSection': 496, 'offsetInEndSection': 620, 'text': ' ANP and BNP are elucidated to be the cardiac hormone mainly secreted from the atrium, and from the ventricle, respectively.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8100590'}, {'offsetInBeginSection': 659, 'offsetInEndSection': 830, 'text': ' In contrast to atrial natriuretic peptides (ANP/NT-proANP), which originate mainly from atrial tissue, BNP related peptides are produced mainly from ventricular myocytes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14987573'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 72, 'text': 'Atrial and brain natriuretic peptides: Hormones secreted from the heart.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29859763'}, {'offsetInBeginSection': 459, 'offsetInEndSection': 571, 'text': ' Atrial natriuretic peptide (ANP) and brain (or B-type) natriuretic peptide (BNP) are of myocardial cell origin.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14574050'}, {'offsetInBeginSection': 145, 'offsetInEndSection': 309, 'text': 'Atrial natriuretic peptide (ANP) and brain (or B-type) natriuretic peptide (BNP) are secreted from cardiomyocytes in response to atrial or ventricular wall stretch.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15478621'}, {'offsetInBeginSection': 98, 'offsetInEndSection': 248, 'text': 'riuretic peptide (BNP) are primarily produced by, and secreted from, heart tissue. They maintain cardiovascular homeostasis by binding to natriuretic ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30120963'}, {'offsetInBeginSection': 744, 'offsetInEndSection': 894, 'text': 'rom atrial tissue, BNP related peptides are produced mainly from ventricular myocytes. Ventricular (NT-pro)BNP production is strongly upregulated in c', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14987573'}, {'offsetInBeginSection': 121, 'offsetInEndSection': 271, 'text': ') and brain natriuretic peptide (BNP) are delivered predominantly by the heart. Two C-type natriuretic peptides (CNPs) are paracrine messengers, notab', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29978892'}, {'offsetInBeginSection': 289, 'offsetInEndSection': 439, 'text': 'tic and renin-angiotensin systems. Although originally isolated from porcine brain, the BNP gene is expressed in a specific manner in cardiac myocytes', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11558673'}, {'offsetInBeginSection': 88, 'offsetInEndSection': 366, 'text': 'Unlike other members, i.e., atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), which are cardiac hormones secreted from the atrium and ventricle of the heart, respectively, CNP is regarded as an autocrine/paracrine regulator with broad expression in the body.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35741432'}, {'offsetInBeginSection': 111, 'offsetInEndSection': 418, 'text': 'However, there is an accumulating evidence that B-type natriuretic peptide (BNP) and its N-terminal fragment (NT-proBNP) may originate from right ventricle and their concentrations are elevated in patients with acute pulmonary embolism (APE) especially when resulting in right ventricular dysfunction (RVD).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18706401'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 135, 'text': 'B-type natriuretic peptide (BNP) is a hormone mainly secreted by cardiac ventricle myocytes and which is increased in cardiac diseases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12084525'}, {'offsetInBeginSection': 191, 'offsetInEndSection': 341, 'text': 'vasoconstrictive molecules. The major source of plasma BNP is the cardiac ventricles. Elevated plasma BNP concentrations correlate with increased left', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16689366'}, {'offsetInBeginSection': 484, 'offsetInEndSection': 634, 'text': 'de (ANP) and brain (or B-type) natriuretic peptide (BNP) are of myocardial cell origin. BNP is released mainly from the left ventricle in response to ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14574050'}]\n\n\n                 'Where does Brain (or B type) Natriuretic Protein, BNP usually originate from?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"heart\", \"left atrium\", \"right auricle\", \"left ventricle\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 184, 'offsetInEndSection': 402, 'text': \" This retrospective case series included patients with PCG who underwent trabeculotomy using an illuminated microcatheter with the intent of catheterizing the full circumference of Schlemm's canal in a single procedure\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33488009'}, {'offsetInBeginSection': 9, 'offsetInEndSection': 195, 'text': \"To study the effect of 3 Schlemm's canal (SC) microinvasive glaucoma surgery (MIGS) devices on outflow facility.DESIGN: Paired comparisons, randomized design, baseline-controlled study.P\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32672594'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 85, 'text': \"Outflow Facility Effects of 3 Schlemm's Canal Microinvasive Glaucoma Surgery Devices.\", 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32672594'}, {'offsetInBeginSection': 146, 'offsetInEndSection': 282, 'text': \"Previously, blood reflux from Schlemm's canal (SC) after long-standing glaucoma surgery was reported in eyes treated with excisional LOT\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33613251'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 241, 'text': \"AIM: to comparatively evaluate the hypotensive effect of minimally invasive (type 1) and basic (type 2) subscleral removing of the external wall of Schlemm's canal with subsequent laser trabeculopuncture in patients with open-angle glaucoma \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28291197'}, {'offsetInBeginSection': 139, 'offsetInEndSection': 397, 'text': \"Schlemm's canal (SC) is a large, lymphatic-like vessel in the anterior chamber of the eye, which is essential for aqueous humor drainage required to maintain intraocular pressure and is sensitive to defects in blood and lymphatic vascular signaling pathways.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30242758'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 161, 'text': \"Schlemm's canal (SC) is a specialized vascular structure in the eye that functions to drain aqueous humor from the intraocular chamber into systemic circulation.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25061877'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 166, 'text': \"Schlemm's canal (SC) is a unique vascular structure that functions to maintain fluid homeostasis by draining aqueous humor from the eye into the systemic circulation.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25061871'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 409, 'text': \"We have tried to answer the question of whether the endothelium of Schlemm's canal is derived from and retains properties of blood vessels by studying: (1) the development of Schlemm's canal in human fetal eyes; (2) the existence of Weibel-Palade bodies in human neonatal, adult human and adult monkey eyes; and (3) the presence of blood coagulation Factor VIII-related antigen in adult human and monkey eyes.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1426078'}, {'offsetInBeginSection': 1450, 'offsetInEndSection': 1628, 'text': \"Our results indicate that the endothelium of Schlemm's canal is derived from a vascular origin and that even in the adult eye it retains some of the properties of a blood vessel.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1426078'}, {'offsetInBeginSection': 1258, 'offsetInEndSection': 1449, 'text': \"(3) Blood coagulation Factor VIII-related antigen was detected in the endothelium of the collector channels and Schlemm's canal, as well as in the blood vessels of the other parts of the eye.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1426078'}, {'offsetInBeginSection': 454, 'offsetInEndSection': 579, 'text': \" Injecting fluorescein directly in Schlemm's canal proves that in cadaver eyes without glaucoma the lumen is open all around.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/729457'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 182, 'text': \"Differences in parameters of ciliary body and Schlemm's canal in different meridians of the eyeball has been described using histotopographic methods on 20 eyeballs of human corpses.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10581564'}]\n\n\n                 'Where in the body would  Schlemm's canal be found'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"eye\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 155, 'text': \"Friedreich's Ataxia (FRDA) is an autosomal recessive neurodegenerative disorder, affecting dorsal root ganglia (DRG), cerebellar dentate nuclei and heart. \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30065630'}]\n\n\n                 'What is the mode of inheritance of Friedreich\u2019s ataxia?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"autosomal recessive\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 336, 'text': 'Coordinated gene expression allows spatiotemporal control of cellular processes and is achieved by the cotranscription/translation of functionally related genes/proteins. Prokaryotes evolved polycistronic messages (operons) to confer expression from a single promoter to efficiently cotranslate proteins functioning on the same pathway.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35934590'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 212, 'text': 'The arrangement of functionally-related genes in operons is a fundamental element of how genetic information is organized in prokaryotes. This organization ensures coordinated gene expression by co-transcription.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32209657'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 106, 'text': 'Clustering of functionally related genes in operons allows for coregulated gene expression in prokaryotes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24012761'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 124, 'text': 'Operons are clusters of genes that are transcribed as a single message, and regulated by the same gene expression machinery.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16755590'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 208, 'text': 'Bacterial genes are commonly encoded in clusters, known as operons, which share transcriptional regulatory control and often encode functionally related proteins that take part in certain biological pathways.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21690561'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 136, 'text': 'In prokaryotic genomes, related genes are frequently clustered in operons and higher-order arrangements that reflect functional context.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15487932'}, {'offsetInBeginSection': 956, 'offsetInEndSection': 1213, 'text': ' Genes in operons are located next to each other in the same DNA strand, and thus their presence should result in a higher proportion of predicted functional interactions among adjacent genes in the same strand than among adjacent genes in opposite strands.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17671982'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 141, 'text': 'Genes that are part of the same operon in prokaryotes, or have the same expression pattern in eukaryotes, are transcriptionally co-regulated.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12220896'}, {'offsetInBeginSection': 809, 'offsetInEndSection': 956, 'text': 'The presence of operons (polycistronic transcription units formed of functionally related genes) in prokaryotic genomes offers such an alternative.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17671982'}]\n\n\n                 'In prokaryotes, functionally related genes are sometimes positioned adjacent to each other in the genome and can be under the control of the same regulatory machinery. What are these called?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Operons\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 269, 'text': 'Drug delivery to the suprachoroidal space (SCS\u00ae) has become a clinical reality after the 2021 FDA approval of CLS-TA, a triamcinolone acetonide injectable suspension for suprachoroidal use (XIPERE\u00ae), administered via a microneedle-based device, the SCS Microinjector\u00ae. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35868358'}]\n\n\n                 'What is the active ingredient of Xipere?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"triamcinolone acetonide\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 634, 'offsetInEndSection': 736, 'text': ' Face, leg, activity, cry, and consolability (FLACC) scores for postoperative pain were also assessed.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35626783'}, {'offsetInBeginSection': 994, 'offsetInEndSection': 1051, 'text': 'The FLACC and COMFORT scales were utilized to assess pain', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33904220'}, {'offsetInBeginSection': 683, 'offsetInEndSection': 862, 'text': 'Postoperative pain was assessed using the Visual Analogue Scale (VAS), the Wong-Baker Faces Pain Rating Scale, and the Face, Legs, Activity, Cry, and Consolability (FLACC) scale. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35628840'}, {'offsetInBeginSection': 656, 'offsetInEndSection': 791, 'text': 'The pain experience (intense, moderate, or mild) was evaluated by the Face, Legs, Activity, Cry, Consolability-revised scale (FLACC-r).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34599744'}, {'offsetInBeginSection': 1301, 'offsetInEndSection': 1508, 'text': ' Daily assessment and documentation for pain (81%) and sedation (87%) was reported by most of the PICUs, using the preferred validated FLACC scale (54%) and the COMFORT Behavioural scale (48%), respectively.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35361254'}]\n\n\n                 'What is the most commonly used pain scale for the measurement of pain in children?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"FLACC\", \"Face, leg, activity, cry, and consolability\", \"COMFORT Behavioural scale\", \"Faces Pain Scale - Revised\", \"FPS-R\", \"FLACC-r\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 139, 'offsetInEndSection': 327, 'text': 'We utilised a novel DILI causality assessment tool (DILI-CAT), which uses drug-specific liver injury phenotypes, to examine potential DILI in early phase ximelagatran clinical development.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35266155'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 144, 'text': 'A novel phenotype-based drug-induced liver injury causality assessment tool (DILI-CAT) allows for signal confirmation in early drug development.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35266155'}, {'offsetInBeginSection': 1633, 'offsetInEndSection': 1808, 'text': \"DILI-CAT, a clinically intuitive, data-driven, computer-assisted scoring algorithm, is a useful tool for early detection of drug's hepatotoxicity in clinical drug development.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35266155'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 102, 'text': 'A novel quantitative computer-assisted drug-induced liver injury causality assessment tool (DILI-CAT).', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36174069'}]\n\n\n                 'What is DILI-CAT used for?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Drug induced hepatotoxicity scoring algorithm\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 562, 'offsetInEndSection': 756, 'text': 'These results suggest that metabolite-binding mRNAs are possibly involved in eukaryotic gene regulation and that some riboswitches might be representatives of an ancient form of genetic control.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12756322'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 399, 'text': 'Genetic control by metabolite-binding mRNAs is widespread in prokaryotes. These riboswitches are typically located in noncoding regions of mRNA, where they selectively bind their target compound and subsequently modulate gene expression. We have identified mRNA elements in fungi and in plants that match the consensus sequence and structure of thiamine pyrophosphate-binding domains of prokaryotes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12756322'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 311, 'text': 'Metabolite-sensing mRNAs, or \"riboswitches,\" specifically interact with small ligands and direct expression of the genes involved in their metabolism. Riboswitches contain sensing \"aptamer\" modules, capable of ligand-induced structural changes, and downstream regions, harboring expression-controlling elements.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15610857'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 291, 'text': 'Riboswitches are a class of RNA motifs in the untranslated regions of bacterial messenger RNAs (mRNAs) that can adopt different conformations to regulate gene expression. The binding of specific small molecule or ion ligands, or other RNAs, influences the conformation the riboswitch adopts.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36227561'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'Metabolite-sensing mRNAs, or \"riboswitches,\" specifically interact with small ligands and direct expression of the genes involved in their metabolism.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15610857'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 190, 'text': 'Bacteria make extensive use of riboswitches to sense metabolites and control gene expression, and typically do so by modulating premature transcription termination or translation initiation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17468745'}, {'offsetInBeginSection': 141, 'offsetInEndSection': 384, 'text': 'Riboswitches possess a metabolite-sensing system that controls gene regulation in a cis-acting fashion at the initiation of transcriptional/translational level by binding with a specific metabolite and controlling various biochemical pathways.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36275359'}, {'offsetInBeginSection': 151, 'offsetInEndSection': 311, 'text': 'Riboswitches contain sensing \"aptamer\" modules, capable of ligand-induced structural changes, and downstream regions, harboring expression-controlling elements.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15610857'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 148, 'text': 'Regulatory mRNA elements or riboswitches specifically control the expression of a large number of genes in response to various cellular metabolites.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19303767'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 185, 'text': 'The discovery of metabolite-sensing RNA domains with gene regulatory functions, so-called riboswitches, has greatly expanded our view of the structural and functional complexity of RNA.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20009507'}, {'offsetInBeginSection': 435, 'offsetInEndSection': 760, 'text': 'Organisms from all three domains of life, including bacteria, plants and fungi, use TPP-sensing riboswitches to control genes responsible for importing or synthesizing thiamine and its phosphorylated derivatives, making this riboswitch class the most widely distributed member of the metabolite-sensing RNA regulatory system.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16728979'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 164, 'text': 'Riboswitches are metabolite-sensing RNAs, typically located in the non-coding portions of messenger RNAs, that control the synthesis of metabolite-related proteins.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16728979'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 101, 'text': 'Structured mRNA elements called riboswitches control gene expression by binding to small metabolites.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18072940'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 219, 'text': 'Riboswitches are motifs in the untranslated regions (UTRs) of RNA transcripts that sense metabolite levels and modulate the expression of the corresponding genes for metabolite import, export, synthesis, or degradation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22219369'}, {'offsetInBeginSection': 998, 'offsetInEndSection': 1221, 'text': ' The discovery of a riboswitch in eukaryotes that is composed of a single class of thiamine pyrophosphate (TPP) suggests that additional ligand-sensing RNAs may be present to control eukaryotic or mammalian gene expression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31741723'}, {'offsetInBeginSection': 379, 'offsetInEndSection': 604, 'text': ' Newly discovered metabolite-sensing riboswitches have revealed that cellular processes extensively make use of RNA structural modulation to regulate gene expression in response to subtle changes in metabolite concentrations.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19101979'}, {'offsetInBeginSection': 74, 'offsetInEndSection': 237, 'text': 'These riboswitches are typically located in noncoding regions of mRNA, where they selectively bind their target compound and subsequently modulate gene expression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12756322'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 142, 'text': 'Riboswitches are mRNA regulatory elements that control gene expression by altering their structure in response to specific metabolite binding.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23169642'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 225, 'text': \"Riboswitches are gene control elements typically located in the 5' untranslated regions of bacterial mRNAs where they modulate the expression of associated genes in response to elevated concentrations of cellular metabolites.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20061809'}]\n\n\n                 'What process involves metabolite-sensing mRNAs to control gene expression?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Riboswitching\", \"Riboswitch\", \"Riboswitches\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 269, 'text': 'Drug delivery to the suprachoroidal space (SCS\u00ae) has become a clinical reality after the 2021 FDA approval of CLS-TA, a triamcinolone acetonide injectable suspension for suprachoroidal use (XIPERE\u00ae), administered via a microneedle-based device, the SCS Microinjector\u00ae. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35868358'}]\n\n\n                 'Which year was XIPERE approved by the FDA?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"2021\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 529, 'offsetInEndSection': 842, 'text': 'Here we report that targeting the codon-optimized form of the light-driven chloride pump halorhodopsin from the archaebacterium Natronomas pharaonis (hereafter abbreviated Halo) to genetically-specified neurons enables them to be silenced reliably, and reversibly, by millisecond-timescale pulses of yellow light.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17375185'}, {'offsetInBeginSection': 661, 'offsetInEndSection': 891, 'text': 'By using Cal-Light to drive expression of the inhibitory receptor halorhodopsin (eNpHR), which responds to yellow light, we temporarily inhibit the lever-pressing behavior, confirming that the labeled neurons mediate the behavior.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28650460'}, {'offsetInBeginSection': 465, 'offsetInEndSection': 723, 'text': 'We introduced enhanced halorhodopsin (eNpHR), a yellow light-sensitive, membrane-targeting chloride pump, into mouse retinal ganglion cells (RGCs) by intravitreously injecting an adeno-associated virus serotype-2 vector carrying the CMV-eNpHR-EYFP construct.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21483674'}, {'offsetInBeginSection': 597, 'offsetInEndSection': 912, 'text': 'Hippocampal pyramidal neurons were transduced in vivo with a virus carrying an enhanced halorhodopsin (eNpHR), a yellow light activated chloride pump, and acute seizure progression was then monitored behaviorally and electrophysiologically in the presence and absence of illumination delivered via an optical fiber.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23637949'}, {'offsetInBeginSection': 1223, 'offsetInEndSection': 1360, 'text': 'Similarly, archaeon Natronomonas pharaonis (NpHR) expresses a monovalent Cl- channel protein halorhodopsin that responds to yellow light.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27905012'}, {'offsetInBeginSection': 141, 'offsetInEndSection': 380, 'text': 'Towards achieving this goal, light-activated channelrhodopsin-2 (ChR2), a cation channel activated with 480 nm light, and a first generation halorhodopsin (NpHR1.0), an anion pump activated by 580 nm light, have been introduced into hiPSC.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23366158'}, {'offsetInBeginSection': 485, 'offsetInEndSection': 645, 'text': 'In analogy, other excitable cells can be inhibited by expressing Halorhodopsin from Natronomonas pharaonis (NpHR) and subsequent illumination with yellow light.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22815873'}, {'offsetInBeginSection': 140, 'offsetInEndSection': 303, 'text': ' Towards achieving this goal, light-activated channelrhodopsin-2 (ChR2), a cation channel activated with 480 nm light, and a first generation halorhodopsin (NpHR1.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23366158'}, {'offsetInBeginSection': 441, 'offsetInEndSection': 591, 'text': ' retino-tectal pathway. We introduced enhanced halorhodopsin (eNpHR), a yellow light-sensitive, membrane-targeting chloride pump, into mouse retinal g', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21483674'}, {'offsetInBeginSection': 724, 'offsetInEndSection': 1042, 'text': 'Several weeks after the injection, whole-cell recordings made from sSC neurons in slice preparations revealed that yellow laser illumination of the eNpHR-expressing retino-tectal axons, putatively synapsing onto the recorded cells, effectively inhibited EPSCs evoked by electrical stimulation of the optic nerve layer.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21483674'}]\n\n\n                 'What color light does the the inhibitory receptor halorhodopsin (eNpHR) respond to?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"yellow\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 181, 'text': 'A critical regulatory element in many promoters transcribed by RNA polymerase II is the \"TATA\" box, which is located 25-30 nucleotides upstream of the transcription initiation site.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1409643'}, {'offsetInBeginSection': 722, 'offsetInEndSection': 921, 'text': 'About 24% of human genes have a TATA-like element and their promoters are generally AT-rich; however, only approximately 10% of these TATA-containing promoters have the canonical TATA box (TATAWAWR).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17123746'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 104, 'text': 'TBP binding to the TATA box induces a specific downstream unwinding site that is targeted by pluramycin.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9383448'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 281, 'text': 'The TATA-binding protein (TBP) is one of the major components of the human TFIID multiprotein complex. It is important in directing the initiation of RNA transcription at a site immediately downstream of the TATA sequence (TATA box) found in many eukaryotic promoters. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9383448'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 171, 'text': 'The TATA box-binding factor TFIID plays a primary role in the process of transcription initiation by RNA polymerase II and its regulation by various gene-specific factors.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1736286'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 211, 'text': 'The canonical core promoter elements consist of the TATA box, initiator (Inr), downstream core promoter element (DPE), TFIIB recognition element (BRE) and the newly-discovered motif 10 element (MTE).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16522199'}]\n\n\n                 'What regulatory element promotes RNA polymerase II binding as well as the binding of factors that facilitate the unwinding of DNA prior to translation?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"TATA box\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 352, 'offsetInEndSection': 498, 'text': \"We conducted a phase I/II double-blind, comparator-controlled trial with 2 doses of RT001 in Friedreich's ataxia patients (9 subjects each cohort)\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29624723'}, {'offsetInBeginSection': 825, 'offsetInEndSection': 920, 'text': 'Nineteen patients enrolled in the trial, and 18 completed all safety and efficacy measurements.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29624723'}]\n\n\n                 'How many patients with Friedreich's ataxia were included in each cohort of the phase I/II double-blind, comparator-controlled trial of RT001.'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Nine per cohort\", \"9/cohort\", \"18 in total\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 127, 'text': 'Facioscapulohumeral Muscular Dystrophy (FSHD) is in the top three list of all dystrophies with an approximate 1:8000 incidence.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34315378'}, {'offsetInBeginSection': 171, 'offsetInEndSection': 322, 'text': 'It is present worldwide, with a prevalence of around 4 per 100000 and an incidence of about 1 in 20000. Overall lifespan is not affected significantly.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21496633'}]\n\n\n                 'What is the incidence of Facioscapulohumeral Muscular Dystrophy?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"1:8000 to 1:20000\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 513, 'offsetInEndSection': 781, 'text': 'Risdiplam (Evrysdi)-an orally bioavailable, small molecule approved by the US Food and Drug Administration and more recently by the European Medicines Agency for the treatment of patients \u22652 months of age with spinal muscular atrophy-is presented here as a case study.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34620695'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 94, 'text': 'An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35567422'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 248, 'text': 'OBJECTIVE: The US risdiplam expanded access program (EAP; NCT04256265) was opened to provide individuals with Type 1 or 2 spinal muscular atrophy (SMA) who had no satisfactory treatment options access to risdiplam prior to commercial availability. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35567422'}, {'offsetInBeginSection': 152, 'offsetInEndSection': 560, 'text': 'SMN1 produces SMN, a ubiquitously expressed protein, that is essential for the development and survival of motor neurons. Major advances and developments in SMA therapeutics are shifting the natural history of the disease. With three relatively new available therapies, nusinersen (Spinraza), onasemnogene abeparvovec (Zolgensma), and risdiplam (Evrysdi), patients survive longer and have improved outcomes. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35614235'}]\n\n\n                 'Risdiplam is used for treatment of which disease?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"spinal muscular atrophy\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 250, 'text': \"Friedreich's ataxia (FRDA) is an autosomal recessive disease caused by an intronic guanine-adenine-adenine (GAA) triplet expansion in the frataxin (FXN) gene, which leads to reduced expression of full-length frataxin (1-210) also known as isoform 1. \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35573317'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 147, 'text': \"Friedreich's ataxia (FRDA) is an inherited, multisystemic disorder predominantly caused by GAA hyper expansion in intron 1 of frataxin (FXN) gene. \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35663795'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 184, 'text': 'Friedreich ataxia, the most common hereditary ataxia, is a neuro- and cardio-degenerative disorder caused, in most cases, by decreased expression of the mitochondrial protein frataxin.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36107856'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 133, 'text': \"Simultaneous Quantification of Mitochondrial Mature Frataxin and Extra-Mitochondrial Frataxin Isoform E in Friedreich's Ataxia Blood.\", 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35573317'}, {'offsetInBeginSection': 1338, 'offsetInEndSection': 1454, 'text': 'We now report a quantitative assay for frataxin proteoforms in whole blood from healthy controls and FRDA patients. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35573317'}, {'offsetInBeginSection': 1925, 'offsetInEndSection': 2122, 'text': 'The mean levels of mature frataxin in whole blood from healthy controls and homozygous FRDA patients were significantly different (p < 0.0001) at 7.5 \u00b1 1.5 ng/mL and 2.1 \u00b1 1.2 ng/mL, respectively. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35573317'}, {'offsetInBeginSection': 2315, 'offsetInEndSection': 2511, 'text': 'he mean levels of total frataxin in whole blood from healthy controls and homozygous FRDA patients were significantly different (p < 0.0001) at 34.2 \u00b1 4.3 ng/mL and 6.8 \u00b1 4.0 ng/mL, respectively. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35573317'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 123, 'text': \"Friedreich's ataxia is caused by mutations in the FRDA gene that encodes frataxin, a nuclear-encoded mitochondrial protein.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10982187'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 203, 'text': \"Friedreich's ataxia (FRDA) is a progressive neurodegenerative disorder caused by a homozygous GAA repeat expansion mutation in intron 1 of the frataxin gene (FXN), which instigates reduced transcription.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32582297'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 113, 'text': 'Friedreich Ataxia (FA) is a rare neuro-cardiodegenerative disease caused by mutations in the frataxin (FXN) gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35038030'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 154, 'text': \"Friedreich's ataxia, characterized by decreased expression of frataxin protein, is caused by GAA trinucleotide repeats within intron 1 in 98% of patients.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31020006'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 144, 'text': \"Friedreich's ataxia is a neurodegenerative disorder associated with a GAA trinucleotide repeat expansion in intron 1 of the frataxin (FXN) gene.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30159187'}, {'offsetInBeginSection': 124, 'offsetInEndSection': 315, 'text': 'Most patients are homozygous for the expansion of a GAA triplet repeat within the FRDA gene, but a few patients show compound heterozygosity for a point mutation and the GAA-repeat expansion.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10982187'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 190, 'text': \"Friedreich's ataxia (FRDA) is a genetic neurodegenerative disease that is caused by guanine-adenine-adenine (GAA) nucleotide repeat expansions in the first intron of the frataxin (FXN) gene.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32291635'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 198, 'text': \"Friedreich's ataxia (FRDA), the most common autosomal recessively inherited ataxia, is due to a homozygous GAA triplet repeat expansion in the first intron of the FRDA gene in about 96% of patients.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15340363'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 94, 'text': \"Friedreich's ataxia is due to loss of function mutations in the gene encoding frataxin (FRDA).\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9241270'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 113, 'text': 'Friedreich ataxia, an autosomal recessive neurodegenerative disease, is the most common of the inherited ataxias.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10633128'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 101, 'text': \"Mutations in Frataxin (FXN) cause Friedreich's ataxia (FRDA), a recessive neurodegenerative disorder.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27343351'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 148, 'text': 'The genetic mutation in Friedreich ataxia (FRDA) is a hyperexpansion of the triplet-repeat sequence GAA\u00b7TTC within the first intron of the FXN gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22798143'}, {'offsetInBeginSection': 415, 'offsetInEndSection': 575, 'text': \"The expansion of a GAA triplet repeat within the first intron of the frataxin gene, which causes Friedreich's ataxia, was not identified in any of the patients.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10686465'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 208, 'text': \"BACKGROUND: Friedreich's ataxia is an autosomal-recessive cerebellar ataxia caused by mutation of the frataxin gene, resulting in decreased frataxin expression, mitochondrial dysfunction, and oxidative stress\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30624801'}]\n\n\n                 'What gene is mutated in Friedreich's ataxia?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"frataxin\", \"FRDA\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 12, 'offsetInEndSection': 152, 'text': 'Duchenne muscular dystrophy (DMD/Duchenne) is a progressive X-linked muscular disease with an overall incidence of 1:5,000 live male births.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35562557'}, {'offsetInBeginSection': 966, 'offsetInEndSection': 1094, 'text': 'The cumulative incidence of disease was 19.7 per 100,000 male live births and 1 in 5076 live born males were diagnosed with DMD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35754057'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 209, 'text': 'Duchenne muscular dystrophy is a genetically determined disease, linked to the X chromosome, c haracterized clinically by producing progressive muscle weakness, with an incidence of 1 per 3500-6000 males born.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31603849'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 218, 'text': 'Duchenne muscular dystrophy (DMD) is a progressive wasting disease of skeletal and cardiac muscles, representing one of the most common recessive fatal inherited genetic diseases with 1:3500-1:5000 in yearly incidence.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29386334'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 190, 'text': 'INTRODUCTION: Duchenne muscular dystrophy is the most common form of muscular dystrophy, with an incidence of 1/3300 male live births and a prevalence rate in the total population of 3/10000', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25996334'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 177, 'text': 'Duchenne/Becker muscular dystrophy is a severe, recessive, X-linked neuromuscular disease with an incidence of 1/3500 (Duchenne type) and 1/30,000 (Becker type) in newborn boys.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18055393'}, {'offsetInBeginSection': 283, 'offsetInEndSection': 474, 'text': 'Statistics Canada data on annual male births in Nova Scotia were obtained for each year.The overall incidence of 1 per 4700 male births remained stable during the 30-year period of the study.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20080524'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 214, 'text': 'Duchenne muscular dystrophy (DMD) is inherited in an X-linked recessive pattern and occurs at an incidence of 1 in 3500 male births, which means that it is a so-called \"orphan\" or rare disease (frequency < 1/2000).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16114258'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 244, 'text': 'Duchenne muscular dystrophy (DMD) is the most common fatal muscle disease, with an estimated incidence of 1/3500-1/5000 male births, and it is associated with mutations in the X-linked DMD gene encoding dystrophin, the largest known human gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36012442'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 117, 'text': 'Duchenne muscular dystrophy (DMD) is a common inherited disease with a worldwide incidence of 1 in 3,500 male births.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8629099'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 149, 'text': 'Duchenne muscular dystrophy (DMD) is one of the most common and severe X-linked disorders with an incidence of approximately 1 in 3500 newborn males.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7705851'}, {'offsetInBeginSection': 701, 'offsetInEndSection': 955, 'text': 'The cumulative birth incidence of Becker muscular dystrophy (at least 1 in 18 450 male live births) was about one third that of Duchenne muscular dystrophy (1 in 5618 male live births), suggesting that the disorder is more common than previously thought.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1673177'}, {'offsetInBeginSection': 57, 'offsetInEndSection': 207, 'text': 'scular dystrophy in childhood, with a worldwide incidence of one in 5000 live male births. It is due to mutations in the dystrophin gene leading to ab', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28802771'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 203, 'text': 'INTRODUCTION: Duchenne muscular dystrophy is the most common form of muscular dystrophy, with an incidence of 1/3300 male live births and a prevalence rate in the total population of 3/100000 individuals', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25996334'}, {'offsetInBeginSection': 577, 'offsetInEndSection': 727, 'text': 'ur region too. The incidence of Duchenne muscular dystrophy was 1 in 4827 liveborn boys. The figure is in the range of the published data of the incid', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7922631'}, {'offsetInBeginSection': 258, 'offsetInEndSection': 408, 'text': 'ular dystrophies the authors estimate the incidence of DMD at 1/6500 living new born boys. The number of false positives (1,5 p. 1000) is little and, ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7334342'}]\n\n\n                 'What is the incidence of Duchenne Muscular Dystrophy?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"1:5,000 live male births\", \"1 in 5076 live born males\", \"1:3500-1:5000\", \"1 per 3500-6000 males born\", \"1/3300\", \"1 in 3,500 to 5,000 male births\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 109, 'text': 'Bacillus Calmette-Guerin for the Treatment of Non-muscle Invasive Bladder Cancer: History and Current Status.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36274226'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 302, 'text': 'In the past decades, the bacillus Calmette-Guerin (BCG) treatment for non-muscle invasive bladder cancer, especially for intermediate and high-risk groups, is increasingly accepted by multiple guidelines. Currently, the front-line setting for the high-risk group is still intravesical BCG instillation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36274226'}]\n\n\n                 'Which cancer is the BCG vaccine used for?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Non-muscle Invasive Bladder Cancer\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 55, 'text': 'Teclistamab in Relapsed or Refractory Multiple Myeloma.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35661166'}, {'offsetInBeginSection': 199, 'offsetInEndSection': 345, 'text': 'In the phase 1 dose-defining portion of the study, teclistamab showed promising efficacy in patients with relapsed or refractory multiple myeloma.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35661166'}, {'offsetInBeginSection': 1946, 'offsetInEndSection': 2102, 'text': 'CONCLUSIONS: Teclistamab resulted in a high rate of deep and durable response in patients with triple-class-exposed relapsed or refractory multiple myeloma.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35661166'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 105, 'text': 'Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35749004'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 190, 'text': 'BACKGROUND: Teclistamab (JNJ-64007957), a B-cell maturation antigen \u00d7 CD3 bispecific antibody, displayed potent T-cell-mediated cytotoxicity of multiple myeloma cells in preclinical studies.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35749004'}]\n\n\n                 'What disease can be treated with Teclistamab?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Multiple Myeloma\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 164, 'offsetInEndSection': 279, 'text': 'In ECOSPOR III, SER-109, an investigational oral microbiome therapeutic, was superior to placebo in reducing rCDI. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35789381'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 85, 'text': 'SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35045228'}, {'offsetInBeginSection': 197, 'offsetInEndSection': 343, 'text': 'SER-109 is an investigational microbiome therapeutic composed of purified Firmicutes spores for the treatment of recurrent C. difficile infection.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35045228'}, {'offsetInBeginSection': 218, 'offsetInEndSection': 464, 'text': 'We report that the manufacturing steps for SER-109, a purified investigational microbiome therapeutic developed to reduce risk of Clostridioides difficile recurrence, inactivate porcine epidemic diarrhea virus, a model coronavirus for SARS-CoV-2.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36158136'}]\n\n\n                 'SER-109 is developed for prevention of which disease?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"C. difficile\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 104, 'text': 'The dystrophin gene (DMD) is the largest gene in the human genome, mapping on the Xp21 chromosome locus.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28867298'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 155, 'text': 'Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are X-linked recessive disorders caused by mutations of the DMD gene located at Xp21.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19461958'}, {'offsetInBeginSection': 130, 'offsetInEndSection': 255, 'text': 'The disease is caused by deletion, duplication or point mutation of the dystrophin gene, located on the X chromosome (Xp21). ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18935728'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 96, 'text': 'DMD gene which is composed of 79 exons is the largest known gene located on X chromosome (Xp21).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24274981'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 150, 'text': 'Dystrophinopathies are allelic conditions caused by deletions, duplications and point-mutations in the DMD gene, located on the X chromosome (Xp21.2).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33870095'}, {'offsetInBeginSection': 197, 'offsetInEndSection': 276, 'text': 'The disease is caused by mutations in the DMD gene located on the X chromosome.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36361862'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 98, 'text': 'BACKGROUND: The Duchenne muscular dystrophy (DMD) gene is located in the short arm of the X chromo', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24627880'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 154, 'text': 'Duchenne muscular dystrophy (DMD) is an X-linked recessive neuromuscular disorder caused by mutations in the dystrophin DMD gene located at Xp21.1 region.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18471087'}, {'offsetInBeginSection': 401, 'offsetInEndSection': 678, 'text': 'Because the DMD gene is located at Xp21.2, which is one breakpoint of the inv(X), and because its defects are rarely associated with severe mental retardation, the other clinical features of this patient were deemed likely to be associated with the opposite breakpoint at Xq22.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12145744'}, {'offsetInBeginSection': 241, 'offsetInEndSection': 368, 'text': 'Long-range physical mapping has shown that the DMD gene, localized in Xp21, is extremely large, exceeding 2 million base pairs.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/2889148'}, {'offsetInBeginSection': 329, 'offsetInEndSection': 415, 'text': 'The DMD gene, located on Xp21, is the largest human gene in the human genome (2.3 Mb).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24014122'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 193, 'text': 'The Duchenne muscular dystrophy (DMD) gene has been localized to chromosome Xp21 and codes for a 14-kilobase (kb) transcript and a protein called dystrophin, of relative molecular mass 427,000.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/2541343'}, {'offsetInBeginSection': 640, 'offsetInEndSection': 772, 'text': ' The breakpoint in our patient is also located at Xp21, adding evidence for the assignment of this band as the site of the DMD gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/6655672'}, {'offsetInBeginSection': 328, 'offsetInEndSection': 409, 'text': ' The DMD gene, located on Xp21, is the largest human gene in the human genome (2.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24014122'}, {'offsetInBeginSection': 297, 'offsetInEndSection': 381, 'text': ' The present case supports the hypothesis that the DMD gene must be located at Xp21.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/3777020'}, {'offsetInBeginSection': 185, 'offsetInEndSection': 272, 'text': ' The causal gene of DMD is the largest one in human that locates in the region of Xp21.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28247611'}, {'offsetInBeginSection': 400, 'offsetInEndSection': 441, 'text': ' Because the DMD gene is located at Xp21.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12145744'}, {'offsetInBeginSection': 39, 'offsetInEndSection': 189, 'text': 'n coded by the Duchenne muscular dystrophy (DMD) gene located on the X-chromosome. Truncating mutations in the DMD gene cause loss of dystrophin and t', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28028563'}, {'offsetInBeginSection': 71, 'offsetInEndSection': 221, 'text': 'r disorder caused by mutations in the dystrophin DMD gene located at Xp21.1 region. Up to 65% of the patients present dystrophin gene deletions. Mothe', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18471087'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 161, 'text': 'BACKGROUND: Duchenne muscular dystrophy (DMD) is caused by a defective gene located on the X-chromosome, responsible for the production of the dystrophin protein', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28740938'}, {'offsetInBeginSection': 100, 'offsetInEndSection': 250, 'text': 'l muscle disorders, caused by mutations in the dystrophin gene located in Xp21. DMD occurs with the incidence 1:3500, BMD with the incidence of 1:18,5', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19837995'}, {'offsetInBeginSection': 17, 'offsetInEndSection': 167, 'text': 'ne (DMD) is the largest gene in the human genome, mapping on the Xp21 chromosome locus. It spans 2.2Mb and accounts for approximately 0,1% of the enti', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28867298'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 287, 'text': 'Duchenne muscular dystrophy (DMD), glycerol kinase deficiency (GKD), and adrenal hypoplasia congenita (AHC) can occur together as part of a contiguous gene syndrome located at chromosome Xp21, GKD can manifest with recurrent episodes of vomiting, acidemia, mental retardation, or stupor.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19078586'}, {'offsetInBeginSection': 77, 'offsetInEndSection': 227, 'text': 'inked recessive disorders caused by mutations of the DMD gene located at Xp21. In DMD patients, dystrophin is virtually absent; whereas BMD patients h', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19461958'}, {'offsetInBeginSection': 22, 'offsetInEndSection': 172, 'text': 'rophy (DMD) is a dystrophinopathy, and its associated gene is located on Xp21. Moreover, utrophin, a recently identified structural homologue of dystr', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12619170'}, {'offsetInBeginSection': 96, 'offsetInEndSection': 246, 'text': ' disease in children, resulting from a defect in the DMD gene located on Xp21.2. The new emerging treatment using exon skipping strategy is tailored t', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31661024'}, {'offsetInBeginSection': 303, 'offsetInEndSection': 453, 'text': \"resent case supports the hypothesis that the DMD gene must be located at Xp21. In this study, involvement of the father's chromosomes in the transloca\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/3777020'}, {'offsetInBeginSection': 364, 'offsetInEndSection': 514, 'text': ' only later was it diagnosed as DMD. Because the DMD gene is located at Xp21.2, which is one breakpoint of the inv(X), and because its defects are rar', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12145744'}, {'offsetInBeginSection': 124, 'offsetInEndSection': 274, 'text': 'letion, duplication or point mutation of the dystrophin gene located at Xp 21.2. In the present study DNA from seventy unrelated patients clinically d', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16936400'}, {'offsetInBeginSection': 60, 'offsetInEndSection': 210, 'text': 'inked diseases resulting from a defect in the dystrophin gene located on Xp21. DMD is the most frequent neuromuscular disease in humans (1/3500 male n', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12488581'}]\n\n\n                 'Where is the DMD gene located?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Xp21 chromosome locus\", \"X-linked recessive disorders caused by mutations of the DMD gene located at Xp21\", \"X chromosome (Xp21)\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 497, 'offsetInEndSection': 724, 'text': 'The combination of chemotherapy and immunotherapy is a potential therapeutic option for PD-L1-positive mTNBC, as the FDA recently approved atezolizumab (Tecentriq) and pembrolizumab (Keytruda) in combination with chemotherapy. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33983696'}]\n\n\n                 'Which form of breast cancer has Keytruda been FDA approved for?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"triple-negative breast cancer\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 477, 'text': 'Blue diaper syndrome (BDS) (Online Mendelian Inheritance in Man number 211000) is an extremely rare disorder that was first described in 1964. The characteristic finding is a bluish discoloration of urine spots in the diapers of affected infants. Additional clinical features of the first described patients included diarrhea, inadequate weight gain, hypercalcemia, and nephrocalcinosis. An intestinal defect of tryptophan absorption was postulated as the underlying pathology.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29610180'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 120, 'text': 'We describe the ocular abnormalities seen in a new metabolic disease which is deficient in the transport of tryptophan. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1818237'}]\n\n\n                 'Which amino acid in implicated in the Blue diaper syndrome?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"tryptophan\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 232, 'text': \"Friedreich's ataxia (FRDA) is an autosomal recessive neurodegenerative disorder caused by a triplet guanine-adenine-adenine (GAA) repeat expansion in intron 1 of the FXN gene, which leads to decreased levels of the frataxin protein.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35850241'}, {'offsetInBeginSection': 225, 'offsetInEndSection': 403, 'text': \"The classic form of autosomal recessive ataxia, Friedreich's ataxia (FA), is now known to be due to an intronic expansion of a guanine-adenine-adenine (GAA)-trinucleotide repeat.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9630233'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 152, 'text': \"Friedreich's Ataxia (FA) is the commonest genetic cause of ataxia and is associated with the expansion of a GAA repeat in intron 1 of the frataxin gene.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16581313'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 110, 'text': \"Reduced expression of the mitochondrial protein Frataxin (FXN) is the underlying cause of Friedreich's ataxia.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25831023'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 161, 'text': 'Friedreich Ataxia (FA) is the most common hereditary ataxia, caused by abnormal expansion of the GAA triplet of the first intron of the X25 gene on chromosome 9.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24152405'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 162, 'text': 'BACKGROUND: Friedreich ataxia (FA), the most common hereditary ataxia, is caused by pathological expansion of GAA repeats in the first intron of the X25 gene on c', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16344344'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 113, 'text': 'Friedreich Ataxia (FA) is a rare neuro-cardiodegenerative disease caused by mutations in the frataxin (FXN) gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35038030'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 125, 'text': \"Friedreich's ataxia (FA) is an inherited neurodegenerative disorder caused by decreased expression of frataxin (FXN) protein.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35289725'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 173, 'text': 'BACKGROUND: Friedreich ataxia (FA), the most common hereditary ataxia, is caused by pathological expansion of GAA repeats in the first intron of the X25 gene on chromosome 9', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16344344'}]\n\n\n                 'What is the cause of Friedreich's Ataxia (FA)?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"triplet guanine-adenine-adenine (GAA) repeat expansion in intron 1 of the FXN gene\", \"triplet repeat in the FXN gene\", \"GAA repeat expansion\", \"GAA repeat expansion in intron 1 of the FXN gene\", \"FXN Gene Mutation\", \"riplet guanine-adenine-adenine (gaa) repeat expansion in intron 1 of the fxn gene\", \"frataxin deficiency\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 331, 'text': 'Oncogenes are gain-of-function mutations of normal regulatory genes or proto-oncogenes. Originally discovered in retroviruses initiating a variety of animal and avian cancers, oncogenes are believed to be important contributors to human carcinogenesis. Proto-oncogenes are altered by point mutation, amplification or rearrangement.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10697588'}, {'offsetInBeginSection': 340, 'offsetInEndSection': 599, 'text': 'Aberrant proteolysis with oncogenic potential is elicited by two major mechanisms: defective degradation of positive cell cycle regulators (i.e., proto-oncoproteins) and enhanced degradation of negative cell cycle regulators (i.e., tumor suppressor proteins).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12665054'}]\n\n\n                 'What are positive cell-cycle regulators that can cause cancer when mutated called?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Proto-oncogenes\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 125, 'text': 'Hereditary angioedema (HAE) is a rare autosomal dominant disorder caused by mutations of the SERPING1 or the Factor 12 genes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27965672'}]\n\n\n                 'What is the inheritance pattern of hereditary angioedema?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"autosomal dominant\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 97, 'text': \"Friedreich's ataxia is classically considered a disease with onset in the first or second decade.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31467149'}, {'offsetInBeginSection': 57, 'offsetInEndSection': 218, 'text': \" age of 25. Rare variants have been described, such as late-onset Friedreich's ataxia and very-late-onset Friedreich's ataxia, occurring after 25 and 40 years, r\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26388117'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 108, 'text': 'The onset of Friedreich ataxia (FA) was before 10 years of age in 36 out of 95 personally observed patients.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8677022'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 299, 'text': 'Friedreich ataxia (FRDA), the most common autosomal recessive neurodegenerative disease among Europeans and people of European descent, is characterized by an early onset (usually before the age of 25), progressive ataxia, sensory loss, absence of tendon reflexes and pyramidal weakness of the legs.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11586299'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 137, 'text': \"Very late-onset Friedreich's ataxia (VLOFA) is characterized by symptomatic onset after 40 years of age and, usually, a benign phenotype.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16092110'}, {'offsetInBeginSection': 394, 'offsetInEndSection': 634, 'text': 'Onset is usually in the first or second decade of life; however, late-onset cases of Freidreich ataxia (LOFA), after the age of 25 years, and very late-onset cases of Freidreich ataxia (VLOFA), after the age of 40 years, have been reported.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25685137'}, {'offsetInBeginSection': 273, 'offsetInEndSection': 369, 'text': 'Disease begins after the age of 25 in occasional patients (late-onset Friedreich ataxia (LOFA)).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26754264'}, {'offsetInBeginSection': 871, 'offsetInEndSection': 1101, 'text': \"ing Scale and EQ-5D. The Friedreich's ataxia cohort was subdivided into three groups: early disease onset (\u226414 years), intermediate onset (15-24 years), and late onset (\u226525 years), which were compared for clinical characteristics \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25566998'}, {'offsetInBeginSection': 272, 'offsetInEndSection': 369, 'text': ' Disease begins after the age of 25 in occasional patients (late-onset Friedreich ataxia (LOFA)).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26754264'}]\n\n\n                 'What is usually the onset age of Friedreich's Ataxia?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"first or second decade\", \"before age 25\", \"the first or second decade\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 219, 'text': 'Cost-utility analysis of cemented hemiarthroplasty versus hydroxyapatite-coated uncemented hemiarthroplasty for the treatment of displaced intracapsular hip fractures : the World Hip Trauma Evaluation 5 (WHiTE 5) trial.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35909375'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 219, 'text': 'A randomized clinical trial of low dose single antibiotic-loaded cement versus high dose dual antibiotic-loaded cement in patients receiving a hip hemiarthroplasty after fracture: A protocol for the WHiTE 8 COPAL study.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33630700'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 137, 'text': 'The World Hip Trauma Evaluation Study 3: Hemiarthroplasty Evaluation by Multicentre Investigation - WHITE 3: HEMI - An Abridged Protocol.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26825319'}, {'offsetInBeginSection': 253, 'offsetInEndSection': 405, 'text': 'METHODS AND ANALYSIS: The World Hip Trauma Evaluation (WHiTE) was set up to measure outcome in a comprehensive cohort of UK patients with hip fracture. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27797994'}]\n\n\n                 'What disease was the topic of the World Hip Trauma Evaluation (WHiTE) trial?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"hip fracture\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 690, 'offsetInEndSection': 854, 'text': 'Omaveloxolone (RTA 408) is an activator of Nrf2 and an inhibitor of NF\u03baB, possessing antioxidative and anti-inflammatory activities in mitochondrial bioenergetics. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34573098'}]\n\n\n                 'What is the alternative name of RTA 408?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Omaveloxolone\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 167, 'offsetInEndSection': 285, 'text': 'SMA is a monogenic pathology that originates from the loss of the SMN1 gene in most cases or mutations in rare cases. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36375840'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 156, 'text': 'Spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative disorder caused by defects in the survival motor neuron 1 (SMN1) gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35643151'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 152, 'text': 'Loss or deletion of survival motor neuron 1 gene (SMN1) is causative for a severe and devastating neuromuscular disease, Spinal Muscular Atrophy (SMA). ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35614235'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 243, 'text': 'Spinal muscular atrophy (SMA) is a neurodegenerative disorder caused by mutations in SMN1 (encoding survival motor neuron protein (SMN)). Reduced expression of SMN leads to loss of \u03b1-motor neurons, severe muscle weakness and often early death.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35927425'}, {'offsetInBeginSection': 114, 'offsetInEndSection': 299, 'text': 'The primary cause of most, if not all, forms of childhood-onset spinal muscular atrophy appears to be the homozygous loss of the telomeric copy of the survival motor neuron (SMNT) gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9225684'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 114, 'text': 'Spinal muscular atrophy (SMA) is caused by loss-of-function mutations in the survival of motoneuron gene 1 (SMN1).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31127156'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 166, 'text': 'Spinal muscular atrophy (SMA) is caused by the low levels of survival motor neuron (SMN) protein and is characterized by motor neuron degeneration and muscle atrophy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28811488'}, {'offsetInBeginSection': 196, 'offsetInEndSection': 424, 'text': 'Although the major cause of SMA is autosomal recessive exon deletions or loss-of-function mutations of survival motor neuron 1 (SMN1) gene, next generation sequencing technologies are increasing the genetic heterogeneity of SMA.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35126465'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 152, 'text': 'Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease caused by deletions or mutations in the survival motor neuron (SMN1) gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31371553'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 196, 'text': 'Spinal muscular atrophy (SMA) is caused by homozygous mutation or deletion of the SMN1 gene encoding survival of motor neuron (SMN) protein, resulting in the selective loss of alpha-motor neurons.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19535574'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 94, 'text': 'Chronic low levels of survival motor neuron (SMN) protein cause spinal muscular atrophy (SMA).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30010942'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 113, 'text': 'The underlying cause of spinal muscular atrophy (SMA) is a deficiency of the survival motor neuron (SMN) protein.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27299569'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 137, 'text': 'Spinal muscular atrophy (SMA) is a neurodegenerative disorder caused by mutations in SMN1 (encoding survival motor neuron protein (SMN)).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35927425'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 219, 'text': 'Spinal muscular atrophy (SMA) is an autosomal recessive genetic disorder caused by survival motor neuron (SMN) protein deficiency leading the loss of motor neurons in the anterior horns of the spinal cord and brainstem.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29799103'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 139, 'text': 'Spinal muscular atrophy (SMA) is caused by SMN1 gene deletions or mutations, and ALS is the most frequent motor neuron condition in adults.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12427909'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 161, 'text': 'Spinal Muscular Atrophy (SMA) is caused by genetic mutations in the SMN1 gene, resulting in drastically reduced levels of Survival of Motor Neuron (SMN) protein.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30368521'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 164, 'text': 'Spinal muscular atrophy (SMA) is a devastating neuromuscular disorder caused by recessive mutations in the SMN1 gene, globally affecting ~8-14 newborns per 100,000.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36142791'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 95, 'text': 'Spinal Muscular Atrophy (SMA) is a neuromuscular disorder caused by mutations in the SMN1 gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30065610'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 119, 'text': 'Spinal muscular atrophy (SMA) is a neuromuscular genetic disease caused by reduced survival motor neuron (SMN) protein.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34217376'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 91, 'text': 'Classic spinal muscular atrophy (SMA) is caused by mutations in the telomeric copy of SMN1.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11528396'}, {'offsetInBeginSection': 104, 'offsetInEndSection': 254, 'text': ' cause of infantile mortality. SMA is caused by mutation or deletion of Survival Motor Neuron-1 (SMN1). The clinical features of the disease are cause', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20392710'}]\n\n\n                 'What is the cause of Spinal Muscular Atrophy (SMA)?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"mutations in SMN1 (encoding survival motor neuron protein (SMN))\", \"Reduced expression of SMN\", \"Loss or deletion of survival motor neuron 1 gene (SMN1)\", \"defects in the survival motor neuron 1 (SMN1) gene\", \"loss of the SMN1 gene\", \"loss of the SMN1 gene in most cases or mutations in rare cases\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 711, 'offsetInEndSection': 1109, 'text': 'Recent results from the PEACHTREE trial (ClinicalTrials.gov Identifier: NCT02595398), a phase III trial with two suprachoroidal injections of CLS-TA at 0 and 12 weeks with follow up lasting 24 weeks, showed the significant improvement in visual acuity and reduction in central subfield thickness, all without increasing the risk of elevated intraocular pressure or accelerated cataract progression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34322164'}]\n\n\n                 'What was the phase of the clinical trial PEACHTREE?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"three\", \"III\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 86, 'text': \"Randomized, clinical trial of RT001: Early signals of efficacy in Friedreich's ataxia.\", 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29624723'}, {'offsetInBeginSection': 352, 'offsetInEndSection': 500, 'text': \"We conducted a phase I/II double-blind, comparator-controlled trial with 2 doses of RT001 in Friedreich's ataxia patients (9 subjects each cohort). \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29624723'}]\n\n\n                 'In what type of clinical trial has RT001 been evaluated against Friedreich's ataxia?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"phase I/II double-blind, randomized, comparator-controlled trial\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 165, 'offsetInEndSection': 464, 'text': 'METHODS: We conducted a phase 1 clinical trial to assess the safety and pharmacokinetics of L9LS, a next-generation antimalarial monoclonal antibody, and its protective efficacy against controlled human malaria infection in healthy adults who had never had malaria or received a vaccine for malaria.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35921449'}, {'offsetInBeginSection': 2119, 'offsetInEndSection': 2300, 'text': 'CONCLUSIONS: In this small trial, L9LS administered intravenously or subcutaneously protected recipients against malaria after controlled infection, without evident safety concerns.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35921449'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 152, 'text': 'L9LS, a potent and safe antimalarial monoclonal antibody, demonstrated 88% protective efficacy against infection in a phase 1 trial in healthy adults.1 ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36260982'}]\n\n\n                 'L9LS was developed for which disease?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"malaria\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 102, 'text': 'Design and synthesis of proteolysis targeting chimeras (PROTACs) as an EGFR degrader based on CO-1686.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35594654'}, {'offsetInBeginSection': 241, 'offsetInEndSection': 365, 'text': 'The emerging technology proteolysis targeting chimera (PROTAC) could be an alternative strategy to overcome these problems. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35594654'}]\n\n\n                 'What does PROTACs stand for?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"proteolysis targeting chimeras\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 253, 'text': 'Leigh syndrome (LS), or subacute necrotizing encephalomyelopathy, is the most common childhood mitochondrial encephalopathy, accounting for more than 50% of cases in this age group. Its estimated incidence is 1:40,000 - 1:77,000 liveborn infants a year.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24299589'}, {'offsetInBeginSection': 182, 'offsetInEndSection': 253, 'text': 'Its estimated incidence is 1:40,000 - 1:77,000 liveborn infants a year.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24299589'}, {'offsetInBeginSection': 834, 'offsetInEndSection': 917, 'text': 'Leigh syndrome occurs with an estimated frequency of 1:77,000-1:34,000 live births.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18651330'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 91, 'text': 'Leigh syndrome is a neurodegenerative disorder with an incidence of 1\\u2009:\\u200940,000 live births.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34868319'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 94, 'text': 'Leigh syndrome is a progressive neurodegenerative disorder, affecting 1 in 40,000 live births.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26725255'}, {'offsetInBeginSection': 133, 'offsetInEndSection': 210, 'text': 'It has an incidence of 1 in 77,000 live births worldwide with poor prognosis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30392038'}]\n\n\n                 'What is the incidence of Leigh syndrome?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"1:40,000 - 1:77,000 liveborn infants a year\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 543, 'offsetInEndSection': 892, 'text': 'In the United States, zanubrutinib, a next-generation BTK inhibitor, has been approved for treating adults with mantle cell lymphoma who have received at least one prior therapy, for adults with Waldenstr\u00f6m macroglobulinemia, and for adults with relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based therapy. B', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35651781'}, {'offsetInBeginSection': 2451, 'offsetInEndSection': 2587, 'text': 'To reduce these side effects, zanubrutinib, a next-generation BTK inhibitor, was designed to block BTK more specifically than ibrutinib.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35651781'}]\n\n\n                 'What does Zanubrutinib inhibit?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Bruton tyrosine kinase\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 96, 'text': 'Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36255686'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 170, 'text': 'Cabotegravir extended-release (ER) injectable suspension (Apretude\u2122) is the first long-acting injectable option to be approved for HIV-1 pre-exposure prophylaxis (PrEP). ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36255686'}, {'offsetInBeginSection': 465, 'offsetInEndSection': 694, 'text': 'Cabotegravir ER injectable suspension is indicated in the USA for PrEP to reduce the risk of sexually acquired HIV-1 infection in at-risk adults and adolescents weighing \u2265\\u200935 kg who have a negative HIV-1 test prior to initiation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36255686'}, {'offsetInBeginSection': 1086, 'offsetInEndSection': 1312, 'text': 'With its convenient, less-frequent dosing schedule and its long-acting formulation enabling intramuscular administration, cabotegravir ER injectable suspension represents a novel and efficacious alternative to daily oral PrEP.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36255686'}]\n\n\n                 'What is Apretude used for?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"HIV-1 pre-exposure prophylaxis\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 100, 'text': 'Outcomes of Ublituximab compared to Teriflunomide for relapsing multiple sclerosis: A meta-analysis.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35779372'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 104, 'text': 'Ublituximab is an anti-CD20 antibody that immunomodulates B-cells for relapsing multiple sclerosis (MS).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35779372'}, {'offsetInBeginSection': 826, 'offsetInEndSection': 1348, 'text': \" In the second part of the review, we summarize medications that have targeted B cells in patients with MS and their current position in the therapeutic armamentarium based on clinical trials and real-world data. Covered therapeutic strategies include the targeting of surface molecules such as CD20 (rituximab, ocrelizumab, ofatumumab, ublituximab) and CD19 (inebilizumab), and molecules necessary for B-cell activation such as B cell activating factor (BAFF) (belimumab) and Bruton's Tyrosine Kinase (BTK) (evobrutinib).\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35570581'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 65, 'text': 'Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36001711'}, {'offsetInBeginSection': 126, 'offsetInEndSection': 207, 'text': 'Ublituximab is being evaluated for the treatment of relapsing multiple sclerosis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36001711'}, {'offsetInBeginSection': 1973, 'offsetInEndSection': 2248, 'text': 'CONCLUSIONS: Among participants with relapsing multiple sclerosis, ublituximab resulted in lower annualized relapse rates and fewer brain lesions on MRI than teriflunomide over a period of 96 weeks but did not result in a significantly lower risk of worsening of disability. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36001711'}, {'offsetInBeginSection': 815, 'offsetInEndSection': 908, 'text': 'The glycoengineered antibody ublituximab is the next anti-CD20 therapy about to be approved. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35869335'}, {'offsetInBeginSection': 707, 'offsetInEndSection': 923, 'text': 'On the other hand, the anti-CD52 monoclonal antibody alemtuzumab and the anti-CD20 monoclonal antibodies rituximab, ocrelizumab, ofatumumab, and ublituximab work via eliminating selected pathogenic cell populations. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35378683'}]\n\n\n                 'What disease is treated with Ublituximab?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"multiple sclerosis\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 186, 'text': 'Palmar erythema (\"liver palms\") was seen in 32/100 consecutive patients with classical rheumatoid arthritis and in 10/100 patients with various other internal diseases (p less than 0.001', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/3830522'}, {'offsetInBeginSection': 193, 'offsetInEndSection': 373, 'text': 'Palmar erythema commonly presents as symmetric, blanchable, slightly warm, nonscaling erythema, most frequently involving the thenar and hypothenar eminences of the palmar surface.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22474732'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 188, 'text': 'Palmar erythema (\"liver palms\") was seen in 32/100 consecutive patients with classical rheumatoid arthritis and in 10/100 patients with various other internal diseases (p less than 0.001).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/3830522'}]\n\n\n                 'What is Palmar Erythema?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"redness of the palms\", \"liver palms\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 387, 'text': 'Oculopharyngeal muscular dystrophy (OPMD) is a late-onset intractable myopathy, characterized by slowly progressive ptosis, dysphagia, and proximal limb weakness. It is caused by the abnormal expansion of the alanine-encoding (GCN)n trinucleotide repeat in the exon 1 of the polyadenosine (poly[A]) binding protein nuclear 1 gene (11-18 repeats in OPMD instead of the normal 10 repeats).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33805441'}, {'offsetInBeginSection': 179, 'offsetInEndSection': 277, 'text': 'A common cause of OPMD is the short expansion of a GCG or GCA trinucleotide repeat in PABPN1 gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34225694'}]\n\n\n                 'What is the cause of Oculopharyngeal Muscular Dystrophy (OPMD)?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"expansion of the alanine-encoding (GCN)n trinucleotide repeat in the exon 1 of the polyadenosine (poly[A]) binding protein nuclear 1 gene\", \"abnormal expansion of GCN repeat in PABPN1 gene\", \"abnormal expansion of the GCN repeat in the polyadenosine binding protein nuclear 1 gene\", \"GCA trinucleotide repeat in PABPN1 gene\", \"short expansion of a GCG or GCA trinucleotide repeat in PABPN1 gene\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 77, 'text': 'EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35172056'}, {'offsetInBeginSection': 158, 'offsetInEndSection': 252, 'text': 'EDP-938, a nonfusion replication inhibitor of RSV, acts by modulating the viral nucleoprotein.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35172056'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 111, 'text': 'EDP-938, a new antiviral with inhibitory activity against the nucleoprotein of the respiratory syncytial virus.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36401806'}, {'offsetInBeginSection': 541, 'offsetInEndSection': 586, 'text': 'EDP-938 has shown high efficacy against RSV. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36401806'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 156, 'text': 'EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33720995'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 90, 'text': 'EDP-938 is a novel non-fusion replication inhibitor of respiratory syncytial virus (RSV). ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33720995'}]\n\n\n                 'Which viral disease can be treated with EDP-938?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Respiratory Syncytial Virus\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 12, 'offsetInEndSection': 168, 'text': 'durvalumab (Imfinzi\u2122; AstraZeneca) is a fully human monoclonal antibody that blocks programmed cell death ligand-1 binding to its receptors (PD-1 and CD80),', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28643244'}, {'offsetInBeginSection': 369, 'offsetInEndSection': 403, 'text': 'durvalumab (IMFINZI\u00ae, Astra-Zeneca', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29571563'}, {'offsetInBeginSection': 375, 'offsetInEndSection': 396, 'text': 'durvalumab (Imfinzi\u00ae)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30917623'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 229, 'text': 'Intravenous durvalumab (Imfinzi\u2122; AstraZeneca) is a fully human monoclonal antibody that blocks programmed cell death ligand-1 binding to its receptors (PD-1 and CD80), resulting in enhanced T-cell responses against cancer cells.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28643244'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 286, 'text': 'Durvalumab (IMFINZI\u00ae), a fully human monoclonal antibody against programmed cell death-ligand 1 (PD-L1), is approved for use in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34731446'}, {'offsetInBeginSection': 211, 'offsetInEndSection': 608, 'text': 'Since 2011, the FDA-approved antibody drugs ipilimumab (Yervoy\u00ae), nivolumab (Opdivo\u00ae), pembrolizumab (Keytruda\u00ae), cemiplimab (Libtayo\u00ae), atezolizumab (Tecentriq\u00ae), durvalumab (Imfinzi\u00ae), and avelumab (Bavencio\u00ae), which block the immune checkpoint proteins, have brought about a significant breakthrough in the treatment of a wide range of cancers, as they can induce durable therapeutic responses.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30917623'}, {'offsetInBeginSection': 113, 'offsetInEndSection': 443, 'text': 'Nevertheless, new therapies have emerged recently, among which PD1 immune checkpoint inhibitors (ICI), such as nivolumab (OPDIVO\u00ae, Bristol-Myers Squibb) and pembrolizumab (KEYTRUDA\u00ae, Merck & Co), or PD-L1 ICI, such as atezolizumab (TECENTRIQ\u00ae, Genentech), durvalumab (IMFINZI\u00ae, Astra-Zeneca), and avelumab (BAVENCIO\u00ae, EMD Serono).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29571563'}, {'offsetInBeginSection': 2406, 'offsetInEndSection': 2741, 'text': 'titumor immunity. This unique mechanism of action in CD103+ DCs may contribute to clinical responses as AZD4635 is being evaluated in clinical trials with IMFINZI (durvalumab, \u03b1PD-L1) in patients with solid malignancies.CONCLUSION: We provide evidence implicating suppression of adaptive and innate immunity by adenosine as a mechanism', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32727810'}]\n\n\n                 'What is the generic name for Imfinzi?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Durvalumab\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 474, 'text': 'The cell cycle (or cell-division cycle) is a series of events that take place in a cell, leading to its division and duplication. Cell division requires cell cycle checkpoints (CPs) that are used by the cell to both monitor and regulate the progress of the cell cycle. Tumor-suppressor genes (TSGs) or antioncogenes are genes that protect the cell from a single event or multiple events leading to cancer. When these genes mutate, the cell can progress to a cancerous state.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26110128'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 378, 'text': 'Deregulation of the cell cycle underlies the aberrant cell proliferation that characterizes cancer and loss of cell cycle checkpoint control promotes genetic instability. During the past two decades, cancer genetics has shown that hyperactivating mutations in growth signalling networks, coupled to loss of function of tumour suppressor proteins, drives oncogenic proliferation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21990031'}, {'offsetInBeginSection': 439, 'offsetInEndSection': 737, 'text': ' We now recognize that tumor suppressor genes regulate diverse cellular activities, including cell cycle checkpoint responses, detection and repair of DNA damage, protein ubiquitination and degradation, mitogenic signaling, cell specification, differentiation and migration, and tumor angiogenesis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14744434'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 133, 'text': 'p53 is a critical tumor-suppressor protein that guards the human genome against mutations by inducing cell-cycle arrest or apoptosis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32359398'}, {'offsetInBeginSection': 1238, 'offsetInEndSection': 1405, 'text': 'Tumor-suppressor gene p16 is an important negative cell-cycle regulator whose functional loss may significantly contribute to malignant transformation and progression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10854145'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 62, 'text': 'Tumor suppressor genes are negative regulators of cell growth.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1399577'}, {'offsetInBeginSection': 340, 'offsetInEndSection': 599, 'text': 'Aberrant proteolysis with oncogenic potential is elicited by two major mechanisms: defective degradation of positive cell cycle regulators (i.e., proto-oncoproteins) and enhanced degradation of negative cell cycle regulators (i.e., tumor suppressor proteins).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12665054'}, {'offsetInBeginSection': 542, 'offsetInEndSection': 738, 'text': ' Genes positively controlling cell cycle checkpoints can be targets for oncogenic activation in cancer, whereas negative regulators, such as tumour suppressor genes, are targeted for inactivation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11327114'}, {'offsetInBeginSection': 142, 'offsetInEndSection': 345, 'text': 'The p27(Kip1) protein belongs to a family of cyclin-dependent kinase-inhibitory proteins that are negative regulators of cell cycle progression and have been proposed as candidate tumor suppressor genes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9815577'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 463, 'text': 'Retinoblastoma 1 (RB1) is the first discovered tumor suppressor gene and recognized as the simple model system whose encoded defective protein can cause a pediatric cancer retinoblastoma. It functions as a negative regulator of the cell cycle through the interactions with members of the E2F transcription factors family. The protein of the RB1 gene (pRB) is engaged in various cell cycle processes including apoptosis, cell cycle arrest and chromatin remodeling.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33682629'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 171, 'text': 'The cell cycle is composed of a series of steps which can be negatively or positively regulated by various factors. Chief among the negative regulators is the p53 protein.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/2046748'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 111, 'text': 'p27Kip1 (p27) is an important negative regulator of the cell cycle and a putative tumor suppressor.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20492666'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 438, 'text': 'It is now evident that the cell cycle machinery has a variety of elements negatively regulating cell cycle progression. However, among these negative regulators in cell cycle control, only 4 have been shown to be consistently involved in the development of human cancers as tumor suppressors: Rb (Retinoblastoma susceptibility protein), p53, and two recently identified cyclin-dependent kinase inhibitors, p16INK4A/MTS1 and p15INK4B/MTS2.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8652807'}]\n\n\n                 'What are negative cell-cycle regulators that can cause cancer when mutated called?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Tumor suppressor genes\", \"Tumor-suppressor genes\", \"tumor suppressors\", \"antioncogenes\", \"anti-oncogenes\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 346, 'text': 'On September 4, 2014, the FDA approved pembrolizumab (KEYTRUDA; Merck Sharp & Dohme Corp.) with a recommended dose of 2 mg/kg every 3 weeks by intravenous infusion for the treatment of patients with unresectable or metastatic melanoma who have progressed following treatment with ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28235882'}]\n\n\n                 'When was Keytruda approved for the treatment of melanoma?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"September 4, 2014\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 241, 'text': 'Oculopharyngeal muscular dystrophy (OPMD) is a late-onset rare muscle disease affecting approximately 1 in 80,000 individuals worldwide. However, it can affect as much as 1:600 individuals in some populations due to a strong founder effect. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36401050'}]\n\n\n                 'What is the incidence of Oculopharyngeal Muscular Dystrophy (OPMD)?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"1:600 to 1:80,000\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 306, 'text': 'BACKGROUND: Hereditary angioedema is characterized by recurrent and unpredictable swellings that are disabling and potentially fatal. Selective inhibition of plasma prekallikrein production by antisense oligonucleotide treatment (donidalorsen) may reduce the frequency of attacks and the burden of disease.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35294812'}, {'offsetInBeginSection': 1698, 'offsetInEndSection': 1880, 'text': 'CONCLUSIONS: Among patients with hereditary angioedema, donidalorsen treatment resulted in a significantly lower rate of angioedema attacks than placebo in this small, phase 2 trial.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35294812'}, {'offsetInBeginSection': 2231, 'offsetInEndSection': 2610, 'text': 'Investigational therapies, including the activated factor XII inhibitor garadacimab and an antisense oligonucleotide targeting plasma prekallikrein messenger RNA (donidalorsen), have shown promise as long-term prophylaxis. Given the requirement of lifelong management for HAE, further research is needed to determine how best to individualize optimal treatments for each patient.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36172291'}]\n\n\n                 'Donidalorsen was tested for which disease?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"hereditary angioedema\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 313, 'text': 'The lac operon is one of the best known gene regulatory circuits and constitutes a landmark example of how bacteria tune their metabolism to nutritional conditions. It is nearly ubiquitous in Escherichia coli strains justifying the use of its phenotype, the ability to consume lactose, for species identification.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34367115'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 489, 'text': 'Transcription of bacterial genes is controlled by the coordinated action of cis- and trans-acting regulators. The activity and mode of action of these regulators can reflect different requirements for gene products in different environments. A well-studied example is the regulatory function that integrates the environmental availability of glucose and lactose to control the Escherichia colilac operon. Most studies of lac operon regulation have focused on a few closely related strains.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31719176'}, {'offsetInBeginSection': 111, 'offsetInEndSection': 278, 'text': 'In the induced state of the lac pathway, the genes comprising the lac operon are transcribed, leading to the production of proteins that import and metabolize lactose.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34953812'}]\n\n\n                 'What are the proteins that are necessary for the use of lactose in E. coli collectively called?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Lac operon\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 102, 'text': 'Alternative microexon splicing by RBFOX2 and PTBP1 is associated with metastasis in colorectal cancer.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34346508'}, {'offsetInBeginSection': 1073, 'offsetInEndSection': 1320, 'text': 'Finally, we found that changes in the pattern of microexon splicing were associated with CRC metastasis. Our data thus suggest that altered expression of RBFOX2 and PTBP1 might influence CRC metastasis through the regulation of microexon splicing.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34346508'}]\n\n\n                 'Alternative microexon splicing is associated with metastasis in which cancer?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Colorectal cancer\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 109, 'offsetInEndSection': 213, 'text': \"Kennedy's disease is nearly exclusively caused by mutations in the androgen receptor encoding gene (AR).\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35996994'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 193, 'text': 'Spinal bulbar muscular atrophy (SBMA) is caused by a CAG repeat expansion mutation in the androgen receptor (AR) gene, and mutant AR is presumed to act in motoneurons to cause SBMA.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20689246'}, {'offsetInBeginSection': 125, 'offsetInEndSection': 286, 'text': 'spinal and bulbar muscular atrophy (SBMA), an inherited neuromuscular disorder caused by a CAG trinucleotide repeat expansion in the androgen receptor (AR) gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32773451'}]\n\n\n                 'What is the cause of spinal-bulbar muscular atrophy?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"mutations in the androgen receptor encoding gene (AR)\", \"CAG repeat expansion mutation\", \"CAG trinucleotide repeat expansion in the androgen receptor (AR) gene\", \"a CAG trinucleotide repeat expansion\", \"Androgen receptor gene mutations\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 449, 'offsetInEndSection': 630, 'text': 'SUMMARY: Clinical trials demonstrated that tezepelumab, an anti-TSLP monoclonal antibody, is a promising alternative treatment for asthma that is effective also in nontype 2 asthma.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34608100'}, {'offsetInBeginSection': 60, 'offsetInEndSection': 132, 'text': 'Tezepelumab in adults and adolescents with severe, uncontrolled asthma. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34606305'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 101, 'text': 'In severe, uncontrolled asthma, tezepelumab reduced exacerbations and improved asthma control at 1 y.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34606305'}, {'offsetInBeginSection': 970, 'offsetInEndSection': 1141, 'text': 'Tezepelumab and other anti-alarmins are thus likely to become, in the near future, valuable therapeutic options for the biological treatment of uncontrolled severe asthma.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34572294'}, {'offsetInBeginSection': 1010, 'offsetInEndSection': 1221, 'text': 'Omalizumab, dupilumab, and tezepelumab can directly modulate the ASM in asthma, by specifically blocking the interaction between IgE, IL-4, and TSLP, and their receptors are located on the surface of ASM cells. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34572466'}, {'offsetInBeginSection': 1409, 'offsetInEndSection': 1761, 'text': 'AHR has been suggested as the main treatable trait towards precision medicine in patients suffering from eosinophilic asthma, therefore, well-designed head-to-head trials are needed to compare the efficacy of those mAbs that directly target ASM contractility specifically against the AHR in severe asthma, namely omalizumab, dupilumab, and tezepelumab.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34572466'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 309, 'text': 'Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, an epithelial cytokine involved in asthma pathogenesis. In the phase 2b PATHWAY study (ClinicalTrials.gov identifier: NCT02054130), tezepelumab significantly reduced exacerbations in adults with severe, uncontrolled asthma. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33368307'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 124, 'text': 'Pharmacokinetic and Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33368307'}, {'offsetInBeginSection': 1496, 'offsetInEndSection': 1663, 'text': 'These results support the selection of 210 mg every 4 weeks subcutaneously as the dose for phase 3 studies of tezepelumab in adults and adolescents with severe asthma.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33368307'}]\n\n\n                 'Which disease can be treated using Tezepelumab?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"severe asthma\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 345, 'text': 'Our genetic information is tightly packaged into a rather ingenious nucleoprotein complex called chromatin in a manner that enables it to be rapidly accessed during genomic processes. Formation of the nucleosome, which is the fundamental unit of chromatin, occurs via a stepwise process that is reversed to enable the disassembly of nucleosomes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20444609'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 464, 'text': 'DNA in eukaryotes is packed into chromatin. The basic component of chromatin is the nucleosome consisting of DNA wrapped around a histone octamer. Inside the cell nucleus, chromatin is folded into higher-order structures through various mechanisms, including repositioning of nucleosomes along the DNA, packing of nucleosomes into more condensed 3-dimensional configurations, looping of chromatin fibres, and tethering of chromosomal regions to nuclear structures.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15868422'}, {'offsetInBeginSection': 147, 'offsetInEndSection': 464, 'text': 'Inside the cell nucleus, chromatin is folded into higher-order structures through various mechanisms, including repositioning of nucleosomes along the DNA, packing of nucleosomes into more condensed 3-dimensional configurations, looping of chromatin fibres, and tethering of chromosomal regions to nuclear structures.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15868422'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 90, 'text': 'Chromatin is a tightly packaged structure of DNA and protein within the nucleus of a cell.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34255854'}, {'offsetInBeginSection': 138, 'offsetInEndSection': 272, 'text': 'The basic unit of chromatin is the nucleosome, which consists of a short piece of DNA wrapped around a core of eight histone proteins.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28058066'}, {'offsetInBeginSection': 273, 'offsetInEndSection': 469, 'text': 'In addition to their role in packaging DNA, nucleosomes impact the regulation of essential nuclear processes such as replication, transcription, and repair by controlling the accessibility of DNA.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28058066'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 179, 'text': 'DNA repair in eukaryotic cells takes place in the context of chromatin, where DNA, including damaged DNA, is tightly packed into nucleosomes and higher order chromatin structures.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23109894'}]\n\n\n                 'Chromatin is tightly packed into what structure inside the nucleus?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Nucleosome\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 12, 'offsetInEndSection': 212, 'text': 'Facial-scapular-humeral myodystrophy Landouzy-Dejerine (FSHD) is an autosomal dominant disease, the basis of its pathogenesis is ectopic expression of the transcription factor DUX4 in skeletal muscle.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30871534'}, {'offsetInBeginSection': 480, 'offsetInEndSection': 584, 'text': 'FSHD2 is caused by the mutations in the protein regulating the methylation status of chromatin - SMCHD1.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30871534'}, {'offsetInBeginSection': 1116, 'offsetInEndSection': 1325, 'text': 'Given the previous report of SMCHD1 mutations in FSHD2 and the clinical presentations consistent with the FSHD phenotype, we conclude that the SMCHD1 mutation is the likely cause of the disease in this family.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24128691'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 96, 'text': 'Exome sequencing identifies a novel SMCHD1 mutation in facioscapulohumeral muscular dystrophy 2.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24128691'}, {'offsetInBeginSection': 275, 'offsetInEndSection': 373, 'text': 'Recently, mutations in SMCHD1 combined with a permissive 4q35 allele were reported to cause FSHD2.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24128691'}, {'offsetInBeginSection': 140, 'offsetInEndSection': 318, 'text': 'Facioscapulohumeral muscular dystrophy type 2 (FSHD2) accounts for approximately 5% of all cases of FSHD and describes patients without a D4Z4 repeat contraction on chromosome 4.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34711481'}, {'offsetInBeginSection': 256, 'offsetInEndSection': 491, 'text': 'Type 1 facioscapulohumeral muscular dystrophy (FSHD) is caused by contraction of D4Z4 repeats on 4q35, whereas type 2 FSHD is associated with mutations of the SMCHD1 or DNMT3B gene in the presence of a disease-permissive 4qA haplotype.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30923442'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 215, 'text': 'Facioscapulohumeral muscular dystrophy (FSHD) 2 is caused by a combination of heterozygous structural maintenance of chromosomes flexible hinge domain containing 1 (SMCHD1) mutation plus DNA hypomethylation on D4Z4.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30327220'}, {'offsetInBeginSection': 808, 'offsetInEndSection': 1037, 'text': 'The less common form of the disease, FSHD2, results from haploinsufficiency of the SMCHD1 gene in individuals carrying a permissive 4qA allele, also leading to the derepression of DUX4, further supporting a central role for DUX4.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28915324'}, {'offsetInBeginSection': 463, 'offsetInEndSection': 613, 'text': 'iduals and 1-10 repeats in patients), and FSHD2 is caused by mutations in SMCHD1 or DNMT3B. Here, we present clinical features and results of genetic ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29402602'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 367, 'text': 'OBJECTIVE: To determine whether congenital arhinia/Bosma arhinia microphthalmia syndrome (BAMS) and facioscapulohumeral muscular dystrophy type 2 (FSHD2), 2 seemingly unrelated disorders both caused by heterozygous pathogenic missense variants in the SMCHD1 gene, might represent different ends of a broad single phenotypic spectrum associated with SMCHD1 dysfunction', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29980640'}]\n\n\n                 'What is the cause of Facioscapulohumeral Muscular Dystrophy type 2 (FSHD2)?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"autosomal dominant disease\", \"ectopic expression of the transcription factor DUX4 in skeletal muscle\", \"mutations in the protein regulating the methylation status of chromatin - SMCHD1\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 213, 'offsetInEndSection': 470, 'text': 'There are two types of the disease: FSHD1 (MIM:158900) and FSHD2 (MIM: 158901), which have different genetic causes but are phenotypically indistinguishable. In FSHD1, partial deletion of the D4Z4 repeats on the 4th chromosome affects the expression of DUX4', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30871534'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 212, 'text': 'Facial-scapular-humeral myodystrophy Landouzy-Dejerine (FSHD) is an autosomal dominant disease, the basis of its pathogenesis is ectopic expression of the transcription factor DUX4 in skeletal muscle.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30871534'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 206, 'text': 'FSHD2 is a rare form of facioscapulohumeral muscular dystrophy (FSHD) characterized by the absence of a contraction in the D4Z4 macrosatellite repeat region on chromosome 4q35 that is the hallmark of FSHD1.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24128691'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 152, 'text': 'The myopathy facioscapulohumeral muscular dystrophy type 1 (FSHD1) is caused by copy number variation of the D4Z4 macrosatellite repeat on chromosome 4.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27822859'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 151, 'text': 'The autosomal dominant myopathy facioscapulohumeral muscular dystrophy (FSHD1, OMIM 158900) is caused by contraction of the D4Z4 repeat array on 4qter.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14634647'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 144, 'text': 'Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is caused by contraction of the D4Z4 repeat array on chromosome 4 to a size of 1-10 units.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24075187'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 225, 'text': 'Facioscapulohumeral muscular dystrophy 1 (FSHD1) is caused by a contraction in the number of D4Z4 repeats on chromosome 4, resulting in relaxation of D4Z4 chromatin causing inappropriate expression of DUX4 in skeletal muscle.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24755953'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 207, 'text': 'Facioscapulohumeral dystrophy type 1 (FSHD1) is caused by contraction of the D4Z4 repeat array on chromosome 4q resulting in sporadic misexpression of the transcription factor DUX4 in skeletal muscle tissue.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31518905'}, {'offsetInBeginSection': 287, 'offsetInEndSection': 526, 'text': 'Autosomal dominant FSHD1 (95% of patients) is characterized by chromatin relaxation induced by pathogenic contraction of a macrosatellite repeat called D4Z4 located on the 4q subtelomere (FSHD1 patients harbor 1 to 10 D4Z4 repeated units).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24882751'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 258, 'text': 'Facioscapulohumeral dystrophy (FSHD) is a progressive muscular dystrophy caused by decreased epigenetic repression of the D4Z4 macrosatellite repeats and ectopic expression of DUX4, a retrogene encoding a germline transcription factor encoded in each repeat.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23593020'}, {'offsetInBeginSection': 137, 'offsetInEndSection': 331, 'text': 'tal muscle. The genetic cause of FSHD1 is contraction of the D4Z4 macrosatellite array on chromosome 4 alleles associated with a permissive haplotype causing infrequent sporadic expression of th', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30122154'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 162, 'text': 'Sporadic DUX4 expression in FSHD myocytes is associated with incomplete repression by the PRC2 complex and gain of H3K9 acetylation on the contracted D4Z4 allele.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30122154'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 104, 'text': 'Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is caused by contraction of the D4Z4 repeat array.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29436205'}, {'offsetInBeginSection': 41, 'offsetInEndSection': 191, 'text': ' dystrophy type 1 (FSHD1) is caused by copy number variation of the D4Z4 macrosatellite repeat on chromosome 4. In unaffected individuals the number o', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27822859'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 175, 'text': 'Facioscapulohumeral muscular dystrophy (FSHD) is caused by the loss of repression at the D4Z4 locus leading to aberrant double homeobox 4 (DUX4) expression in skeletal muscle.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32576599'}]\n\n\n                 'What is the cause of Facioscapulohumeral Muscular Dystrophy type 1 (FSHD1)?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"autosomal dominant disease\", \"partial deletion of the D4Z4 repeats on the 4th chromosome\", \"ectopic expression of the transcription factor DUX4 in skeletal muscle\"]}"}]}
